1.2-Diamido-ethvlene derivatives The present invention relates to novel 1,2-diamido-ethylene derivatives of formula (I) And their use as pharmaceuticals. The invention also concerns related aspets including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I) and especially their use as orexin receptor antagonists. Orexins (orexin A or OX-A and orexin B or OX-B) are novel neuropeptides found in 1998 by two research groups, orexin A is a 33 amino acid peptide and orexin 8 is a 28 amino acid peptide (Sakurai T. et al., Cell, 1998, 92, 573-585). Orexins are produced in discrete neurons of the lateral hypothalamus and bind to G-protein-coupled receptors (OXi and OX2 receptors), The orexin-1 receptor (OX,) is selective for OX-A, and the orexin-2 receptor (OX2) is capable to bind OX-A as well as OX-B. Orexins are found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback inuchanism that regulates feeding behaviour (Sakurai T. etal., Cell, 1998, 92, 573-585). On the other hand, it was also observed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches to narcolepsy as well as insomnia and other sleep disorders (Chemelli R.M, etal., Cell, 1999, 98, 437-451). Orexin receptors are found in the mammalian brain and may have numerous implications in pathologies as known from the literature. The present invention provides 1,2-diamido-ethylene derivatives, which are non-peptide antagonists of human orexin receptors. These compounds are in particular of potential use in the treatment of e.g. eating disorders, drinking disorders, sleep disorders, or cognitive dysfunctions in psychiatric and neurologic disorders. Up to now, several low molecular weight compounds are known having a potential to antagonise either specifically OX1 or OX2, or both receptors at the same time. Ethylene diamine derivatives useful as orexin receptor antagonists are disclosed in WO03/051872. The present invention describes for the first time 1,2-diamido-ethylene derivatives as orexin receptor antagonists. i) A first aspect of the invention consists of 1,2-diamido-ethyiene derivatives of the formula (!) wherein R1 represents hydrogen, (Ci.6)alkyl, (C3.6)cyc!oalkyl, (C3.6)cycloalkyl-(Ci.4)alkyl, or aryl-(Ci-4)alkyl, wherein the aryl is unsubstituted, or mono-substituted, wherein the substituent is selected from the group consisting of (Ci-4)alkyl, (Ci.4)alkoxy, trifluoromethyl, and halogen; R2 represents hydrogen, (Ci.4)alkyl, (C3.6)cycloalkyl, or aryl-(Ci-4)alkyl, wherein the aryl is unsubstituted, or mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci.4)alkyl, (Ci-4)alkoxy, trifluoromethyl, and halogen; wherein R2 and R2 do not represent hydrogen at the same time; R2 represents heterocyclyl, which Is unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci.4)alkyl, (Ci.4)alkoxy, halogen, and trifluoromethyl; A lepresents R" represents (Ci.4)alkyl, bromo, cyclopropyl, or -NR2R®; R2 represents hydrogen, or (Ci.4)alkyl; R2 represents hydrogen, or (Ci.4)alkyl; and D represents aryl, which is unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisling of (Ci.4)alkyl, (Ci-4)alkoxy, trifluoromethyl, trifluoromethoxy, cyano, and halogen. The compounds of formula (I) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. Substituents at a double bond may be present in the Z- or £-configuration unless indicated otherwise. The compounds of formula (I) may thus be present as mixtures ot stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art. Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like. Any reference to a compound of formula (I) is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient. The term "pharmaceutically acceptable salts" refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217. The following paragraphs provide definitions of the various chemical moieties for the compounds according to the invention and are intended to apply uniformly throughout the specification and claims, unless an otherwise expressly set out definition provides a broader or narrower definition. The term "halogen" means fluorine, chlorine, or bromine, preferably fluorine or chlorine. The term "alkyl", alone or in any combination, means a straight-chain or branched-chain alkyl group with the indicated number of carbon atoms. For example, the term "(Ci G)alkyr' means an alkyl group with 1 to 6 carbon atoms. Examples of (Ci.6)alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert.-butyl, n-pentyl, isopentyl, n-hexyl, and 3,3-dimethyl-butyl. The term "(C,.4)alkyr' means an alkyl group with 1 to 4 carbon atoms. Examples of (Ci.4)alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert.-butyl. Preferred are methyl, ethyl, and n-propyl. Most preferred is methyl. Examples of "R2" representing (Ci.6)alkyl are methyl, isobutyl, and 3,3-dimethyl-butyl, preferred is methyl. Examples of "R2" representing (Ci.4)alkyl are methyl, isopropyl, and isobutyl. The term "(C3.6)cycloalkyr' means a saturated cyclic hydrocarbon moiety containing 3-6 carbon atoms. Examples are cyclopropyl, cyclopentyl and cycloiiexyl, preferred is cyclopropyl. The term "(C3.6)cycloalkyl-(Ci-4)alkyr' means a (C3-6)cycloalkyl group as previously defined that is attached to the parent molecular moiety through a (Ci.4)alkyl group as previously defined. Examples are cyclopropyl-methyl, cyclopentyl-methyl and cyclohexyl-methyl, preferred are cyciopropyl-methyl, and cyclohexyl-methyl; most preferred is cyciopropyl-methyl. The term "(Ci.4)alkoxy" means a group of the formula (Ci.4)alkyl-0- in ' hich the term "(Ci.4)alkyr' has the previously given significance. Examples of (Ci.4)alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy and tert.-butoxy. Preferred are methoxy and ethoxy. Most preferred is methoxy. The term "heterocyclyl" means a 8- to 10-membered bicyclic ring containing 1, 2 or 3 heteroatoms, each independently selected from oxygen, nitrogen and sulfur, wherein at least one ring of said bicyclic ring system is aromatic and the bond with which the heterocyclyl is attached to the rest of the molecule is positioned on an aromatic carbon atom of said bicyclic ring system in alpha position to a bridgehead atom as further illustrated in the following examples: V J = bridgehead atom of the bicyclic ring system n - bond with which in these examples the heterocyclyl group may be attached to the rest of the molecule Examples of such heterocyclyl groups are quinoline-8-yl, isoquinoline-1-yl, indol-3-yl, indol-4-yl, indol-7-yl, indazol-3-yl, indazol-4-yl, inda2ol-7-yl, benzofuran-4-yl, benzofuran-7-yl, benzisoxazol-S-yl, benzisoxazol-4-yl, ben2isoxazol-7-yl, benzoxazol-4-yl, benzoxazol-7-yl, benzoxadiazol-4-yl, benzoxadiazol-7-yl, benzothiophene-3-yl, benzothiophene-4-yl, benzothiophene-7-yl, benzthiazol-4-yl, benzthiazol-7-yl, benzoisothiazol-3-yl, ben2oisothiazol-4-yl, benzoisothia2ol-7-y!, benzothiadiazol-4-yl, benzothiadiazol-7-yl, ben2imidazol-4-yl, benzimidazol-7-yl, imidazo[2,1-b]thiazol-3-yl, imidazo[2,1-b]thiazol-5-yl, pyrazolo[1,5-a]pyridine-3-yl, imldazo[1,2-a]pyridine-3-yl, 2,3-dihydro-thieno[3,4-b][1,4]dioxine-5-yl, benzo[1,3]dioxol-4-yl, 2,3-dihydro-benzofuran-4-yl, 2,3-dihydro-benzofuran-7-yl, 4H-ben2o[1,3]dioxin-8-yl, 4H-benzo[1,3]dioxin-5-yl, and 2,3-dihydro-benzo[1,4]dioxin-5-yl. The above-mentioned heterocyclyl groups are unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci.4)alkyl, (Ci-4)alkoxy, halogen, and trifluoromethyl. In "R2" representing "heterocyclyl" said heterocycly! group is preferably unsubstituted, mono-, or di-substituted, wherein the substituents preferably are independently selected from the group consisting of (Ci-4)alkyl. If substituted, indolyl, indazolyl, and imidazo[2,1-b]thiazolyl groups are preferably mono- or di-substituted (preferred mono-substituted) with methyl. 2,3-Dihydro-benzofuranyl, benzo[1,3]dioxol-4-yl, 4H-benzo[1,3]dioxinyl, and 2,3-dihydro-benzo[1,4]dioxin-5-yl groups are preferably unsubstituted. Particular examples of R2 representing "heterocyclyl" are quinoline-8-yl, isoquinoline-1-yl, 1,2-dimethyl-indol-3-yl, 1-methyl-indol 3 yi, indazol-3-yl, 1-methyl-indazol-3-yl, 2-methyl-benzofuran-4-yl, benzofuran 4-yl, benzisoxazole-3-yl, 2-methyl-benzoxa2ole-4-yl, benzoisothiazole-3-yl, imidazo[2,1 b]-thiazole-5-yl, 2-methyl-imidazo[2,1-b]thiazol-5-yl, 3-methyl-imidazo[2,1-b]thiazol 5-yl, 6-methyl-imidazo[2,1 -b]-thiazole-5-yl, pyrazolo[1,5-a]pyridine-3-yl, imida2o[1,2-a]pyridine-3-yl, 2,3-dihydro-thieno[3,4-b][1,4]dioxine-5-yl, 2,3-dihydro-ben2ofuran-4-yl, 2,3-dihydro-benzofuran-7-yl, and 2,3-dihydro-ben2o[1,4]dioxine-5-yl. Preferred examples are 1-methyl-inda2oi-3-yl, benzofuran-4-yl, imidazo[2,1-b]-thiazole-5-yl, 6-methyl-imidazo[2,1-b]-thiazole-5-yl, 3-methyl-imidazo[2,1-b]thiazol-5-yl, and 2,3-dihydro-benzo[1,4]dioxine-5-yl; more preferred examples are 1-methyl-indazol-3-yl, benzofuran-4-yl, and 6-methyl-imidazo[2,1-b]-thiazole-5-yl. The term "aryl", alone or in any combination, means phenyl, wherein the aryl group is unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, trifluoromethyl, trifluoromethoxy, cyano, and halogen. Examples of "D" representing "aryl" are phenyl, 3-methylphenyl, '\ methylphenyi, 3,4-dimethylphenyl, 3-cyanophenyl, 3-methoxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-trifluoromethylphenyl and 4-trifluoromethylphenyl. The term "aryl-(Ci.4)allte( prepared by reaction of 3-chloro-3-(4-fluoro-phenyl)-2-oxo-propionic acid methyl ester with thiourea. LC-MS: tp = 0.75 min; [M+H]" = 253. 2-Amino-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3-methoxy-phenyl)-2-oxo-propionic acid methyl ester with thiourea. LC-MS: tp = 0.75 min; [M+H]' = 265.25 2-Amlno-5-(3-chloro-phenyl)-thiazole-4-carboxylic acid methyl esiei prepared by reaction of 3-chloro-3-(3-chloro-phenyl)-2-oxo-propionic acid methyl ester with thiourea. LC-MS: tp = 0.82 min; [M+H]' = 310.18. 2-Amino-5-phenyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-phenyl-2-oxo-propionic acid methyl ester with thiourea. LC-MS: tp = 0.77 min; [M+H]" - 235. A.1.4. Synthesis of thiazole-4-carboxylic acid derivatives (general procedure) A solution of the respective thiazole-4-carboxylic acid methyl ester (96.2 mmol) iii a mixture of THF (150 mL) and MeOH (50 mL) is treated with 1M aq. NaOH (192 mL). After stirring for 3 h a white suspension is formed and the org. volatiles are removed in vacuo. The remaining mixture is diluted with water (100 mL), cooled in an ice-bath and acidified (pH = 3-4) by addition of 1M aq. HCI. Tlie suspension is filtered and tlie residue is washed with cold water. After drying the corresponding thlazolo-4-carboxylic acid derivative is obtained. 2-Methyl-5-phenyl-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-phenyl-thiazole-4-carboxylic acid rnetiiyl ester. LC-MS: tp = 0.78 min; [M+H]' = 220.01. 2-Wlethyl-5-p-tolyl-thia2ole-4-carboxylic acid prepared by saponification of 2-methyl-5-p-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tn = 0.83 min; [M+H]' = 234.0. 5-(2-Fluoro-phenyl)-2-methyl-thia2ole-4-carboxylicacid prepared by saponification of 5-{3-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: U = 0.82 min; [M+H]" = 238.1. 5-(3-Fluoro-phenyl)-2-methyl-thia2ole-4-carboxylic acid prepared by saponification of 5-(3-fluoro-phenyl)-2-methyl-thiazole~4-carboxylic acid methyl ester. LC-MS: IR - 0.82 min; [M+H]" = 238.1. 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxyiicacld prepared by saponification of 5-(4-fluoro-phenyl)-2-methyl-thiazole-4~carboxylic acid methyl ester. H-NMR (DMSO-dg): 5 - 2.67 (s, 3H); 7.27 (m, 2H); 7.53 (m, 2H); 12.89 (br.s, 1H). 5-(4-Ch[oro-pheny[)-2-methvl-thiazole-4-carboxylic acid prepared by saponification of 5-(4-chloro-phenyl)-2-methyllhiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.85 min; [M+H]" = 253. 2-l\/lethyl-5-(3-trif!uoromethyl-plienyl)-thiazole-4-carboxylicacid prepared by saponification of 2-methyi-5-(3-trifluoromelhyl-phenyt) tiuazole-4-carboxylic acid methyl ester. LC-MS; tp = 0.88 min; [M+HJ' = 287.99. 2-Methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylicacid prepared by saponification of 2-methyl-5-(4-trifluoromethyI-phenyl) ihiazole-4-carboxylic acid methyl ester. LC-MS: tp = 0.90 min; [M+H]" = 287.99. 2-Methyl-5-(3-methoxy-phenyl)-thlazole-4-carboxyl[cacid prepared by saponification of 2-methyl-5-(3-methoxy-phenyl)-thia2ole-4-carboxylic acid methyl ester. LC-MS: IR = 0.80 min; [M+H]" = 250.04. 2-Methyl-5-(3,4-dimethyl-phenyl)-thiazole-4-carboxylicacid prepared by saponification of 2-methyl-5-(3,4-dimethyi-phenyl)-thiazole-4-carboxylic acid metfiyl ester. LC-IVIS; tp = 0.97 nnin; [M+H]' = 382.38. 2-Methyl-5-(3-cyano-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-(3-cyano-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-IVIS: tR - 0,76 min; [M+H]' = 245.25. 2-Amino-5-p-toIyl-thiazole-4-carboxylic acid prepared by saponification of 2-amino-5-m-tolyl-thiazole-4-carboxvlic acid nnethyl ester. LC-MS: tR = 0.64 nnin; [M+H]' = 235.24. 2-Amino-5-/n-to[yl-thiazole-4-carboxyiic acid prepared by saponification of 2-amino-5-m-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tp = 0.65 min; [M+H]" = 235.0. 2-Amino-5-(3-fluoro-phenyl)-tliiazole-4-carboxylicacid prepared by saponification of 2-amino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: U = 0.62 min; [M+H]' = 239.1. 2-Amino-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-amino-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.61 min; [M+H]' = 239. 2-Amino-5-phenyl-thiazole-4-carboxylicacid prepared by saponification of 2-amino-5-phenyl-thiazole-4-carboxylic acid methyl ester. LC-MS: IR = 0.63 min; [M+H]" = 221. 2-Amlno-5-(3-metlioxy-phenyl)-thiazole-4-carboxylicacid prepared by saponification of 2-amino-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: IR = 0.63 min; [M+H]" = 221. 2-Amino-5-(3-cliloro-phenyi)-tlilazo[e-4-carboxylicacid prepared by saponification of 2-amino-5-(3-chloro-phenyl)-thiazole-4-carboxyiic acid methyl ester. LC-MS: tp = 0.63 min; [M+H]" = 221. In an inert atmosphere, copper(ll)bromide (47.3 mmol, 1.0 eq) was suspended in MeCN (200 ml) and cooled to 5-10°C followed by the addition of 3-methylbutyinitrite (71 mmol, 1.45 eq) over 15 min. To this reaction mixture the respective 2-aminothiazole derivative (47.3 mmol, 1 eq) was added in portions over 35 min. at 5-10°C. The reaction mixture was then carefully heated to 65°C and stirnng continued for 2 h. The volatiies were removed under reduced pressure and the black residue was purified by FC (Si02; heptan / EA) to give the products as slightly yellow oils or solids. 2-Bromo-5-/n-tolyl-thia2ole-4-carboxylic acid methyl ester LC-MS:tR = 1.01 min; [M+H]' = 311.79/313.94. 2-Bromo-5-phenyl-thiazole-4-carboxylic acid methyl ester LC-MS: tR = 1.00 min; [M+H]" = 300.10.. 2-Bromo-5-p-tolyl-thlazole-4-carboxyl[c acid methyl ester LC-MS: tp = 1.01 min; [M+H]' = 311,79/313.94. 2-Bromo-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester LC-MS: tR = 0.97 min; [M+H]" = 318.17. To a solution of the respective 2-bromo-5-arylthiazole-2-carboxylic acid methyl ester derivative (3.2 mmol, 1 eq) in THF (5 ml) and methanol (1 ml) was added sodium hydroxide solution (6 ml, 1M). Stirring at room temperature was continued for 14 h. The volatiies were removed under reduced pressure followed by the addition of water (10 ml) to the residue. The pH of the solution was adjusted to 3-4 by the addition of aq HCI. The product precipitated and was isolated by filtration as a colorless solid. 2-Bromo-5-p-tolyl-thiazole-4-carboxylicacid LC-MS: tp = 0.89 min; [M+H] = 300.23. 2-Bromo-5-(3-methoxy-phenyl)-thiazole-4-carboxync acid LC-MS: tR = 0.86 min; [M+Hf = 316.16 A,1.7. Synthesis of 2-cyclopropyl-thiazole-4-carboxylic acid methyl ester derivatives using the Stille reaction Cyclopropyl-tributyl-stannane (10.4 mmol, 1.1 eq) was dissolved in 1,2-dichloroethane followed by the addition of the respective 2-bromo-thiazole derivative (9.5 mmol, 1 eq). The mixture was degassed with Ar or Na for 5 min followed by the addition of bis(trlphenylphosphine)palladlum(ll)dichlorlde (0.47 mmol, 0.05 oq). The reaction mixture was heated to 80°C and stirring continued for 24 h. The solvent was evaporated under reduced pressure and the residue was purified by FC (SiO, ' heptane : EA = 2 : 1) to give the 2-cyclopropyl thiazole derivatives. 2-Cyc[opropyl-5-phenyl-thiazole-4-carboxylic acid methyl ester LC-MS: tR = 0.99 min; [M+H]" = 260.45. 2-Cyclopropyl-5-(3-methyl-phenyl)-thrazole-4-carboxyllc acid methyl ester LC-MS: tR = 0.99 min; [M+H]" = 274.26. 2-Cyclopropyl-5-(3-methoxy-phenyl)-thia2ole-4-carboxylic acid methyl ester LC-MS: tR = 0.96 min; [M+H]+ = 290.30. A.I.8, Hydrolysis of the methyl esters to the carboxylic acids: 2-Cyclopropyl-5-phenyl thiazole-4 carboxylic acid methyl ester (47.4 mmol, 1.0 eq) was dissolved in 185 ml of a mixture of THF/lsOH (125/60, v/v). 1 M aq. NaOH (95 ml, 2.0 eq.) was added and stirring continued overnight. The solvent was stripped off and the residue treated with water (200ml) and adjusted to pH = 3-4 by addition of a solution of 10% citric acid in water. The aq. phase was extracted twice witli each 200 ml of EE. The combined organic phases were dried over NaaSO,,, filtered and evaporated to dryness yielding the desired acids In yields of ca. 85%, which were used for subsequent reactions without further purifications. 2-Cyclopropyl-5-(3-methyl-phenyl)-thiazole-4-carboxylic acid LC-MS: tp = 0.90 min; [M+H]" = 260.23. 2-Cyclopropyl-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid LC-MS: tp = 0.87 min; [M+H]' = 276.27. General Procedure: Synthesis of ((f?S)-2-amino-2-cyclopropyl-ethyl) oarbamic acid tert-butyl ester Step 1: Cyclopropyl-(1-phenyl-etliylamino)-acetonitrile Cyclopropanecarboxaldehyde (43 mmol, 1.05 eq.) was dissolved in a mixture of IVIeOH (59.8 mi), water (53.5 ml) and 25% HCI (41.9 mmol, I.OIeq.). (H-/-)-1-Phenyl-ethylam.ine (41.5 mmol, 1.0 eq.) and KCN (41 5 mmol, 1.0 eq.) are added and the mixture was allowed to stir for 65 h. The solvent was stripped off and the crude product suspended in DCM. The suspension was treated with aq. sat. NaHCOa. The organic phase was dried over Na2S04 and evaporated to dryness. The crude product (7.89 g, 95%) was used for the next step without any further purification. LC-MS: tR = 0.65/0.69 min; [M+H]' = 201.09. Step 2: 1-Cyclopropyl-A/-(1-phenyl-ethyl)-ethane-1,2-diamine LiAIH4 (79.6 mmol, 2.0 eq.) was suspended under argon in dry ether (66 ml) and cooled down to 0°C. Then a solution of cyclopropyl-(1-phenyl-ethylamino)-acelonitriie (39.9 mmol, 1.0 eq.) in dry ether (10 ml) was dropped within 10 min to the suspension under virgous stirring. Stirring continued for 2 h at 0°C and further 2 h at ambient temperature. The reaction solution was cooled to 0°C and water (3.0 ml) followed by 15% NaOH (3.0 ml) were added slowly to the reaction solution. Then 60 ml of THF were added and stirring continued overnight. Tiie mixture was diluted with THF, dried over Na2S04 and evaporated to dryness. The crude product (7.85 g, 96%) was used for the next step without any further purification. LC-MS: tR = na; [M+H]' = 205.10. Step 3: [2-Cyclopropyl-2-(1-phenyl-ethylamino)-ethyl]-carbamic acid tert-buty[ ester 1-Cyclopropyl-A/-(1-phenyl-ethyl)-ethane-1,2-diamine (38.4 mmol, 1.0 eq.) was dissolved in EE (128 mi) and cooled down to 0°C. To this solution was added NEts (57.6 mmol, 1.5 eq.) followed by a 2.5 M solution of BocgO (38.4 mmol, i .0 eq.) in EE. Stirring continued for 66 h at ambient temperature. The organic phase was washed with aq. sat. NaHCOa and dried over Na2S04. After evaporated to dryness the crude product (10.86 g, 93%) was used for the next step without any further purification. LC-MS: tR = 0.78 min; [M+H]" = 305.14. Step 4: ((f?S)-2-Amino-2-cyclopropyl-ethyl)-carbamic acid tert-butyl ester [2-Cyclopropyl-2-(1-phenyl-ethylamino)-ethyl]-carbamic acid tert-butyl ester (35.7 mmol, 1.0 eq.) was dissolved in a mixture of EE/EtOH (142 ml, 1/1, v/v). 10% Pd/C (0.1 eq.) was added and the suspension was treated for 90 h with H2 for 90 h ai 'J bar. The solution filtered over Celite and evaporated to dryness. The crude product was purified by flash chromatography yielding the desired product (5.90 g, 83%) as yellowish oil. LC-MS: tR = 0.58 min; [M+H]' = 201.11. The following (2-amino-ethyl)-carbamic acid tert-butyl ester derivatives ol structure (2) have been synthesized from (+/-)-1-phenyl-ethylamine and itie appiopriate commercially available aldehyde according to the method given above: ((f?S)-2-Amino-4-phenyl-butyl)-carbamic acid tert-butyl ester LC-MS: tR = 0.74 min; [M+H]' = 265.08. ((/7S)-2-Amino-propyl)-carbamic acid tert-butyl ester LC-MS: tR = 0.48 min; [M+H]" = 175.08. ((/?S)-2-Amino-3-phenyl-propyl)-carbamic acid tert-butyl ester LC-MS: tR = 0.70 min; [M+H]" = 251.08. ((flS)-2-Amino-3-methyl-butyl)-carbamic acid tert-butyl ester LC-MS; tp = 0.60 min; [M+H]' - 203.11. ((flS)-2-Amino-4-methyl-pentyl)-carbamic acid tert-butyl ester LC-MS: tR = 0.67 min; [M+H]" = 217.13. B. Preparation of examples Example 1: 2-Methyl-5-phenyl-thiazole-4-carboxyllc acid {(Hij)-2-t(benzofuran-4-carbonyl)-amino]-1-cyclopropyl-ethyl}-methyl-amide Step 1: ((f?S)-2-Cyclopropyl-2-methylamino-ethyl)-carbamic acid teri-bulyl ester ((flS)-2-Amino-2-cyclopropyt-ethyl)-carbannic acid tert-butyl ester (0.75 rnmol, 1.0 eq.) was dissolved in MeOH (7.5 ml) and a 36.5 % solution of formaldehyde in water (0.825 mmol, 1.1 eq.) was added. Stirring continued for 3 h and then NaBH4 (0 99 mmol, 1.4 eq.) was added. Stirring continued overnight and the solvent was stripped off. The crude was dissolved in DCM and the organic phase was washed with aq. sat. NaHCOs and dried over Na2S04. The crude product was used fur the next reaction without any further purification. LC-MS: tn = 0.59 min; [M+H]' = 215.14. Step 2: {(/?S)-2-Cyclopropyl-2-[methyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}-carbamic acid tert-butyl ester 2-Methyi-5-phenyl-thiazole-4-carboxylic acid (0.75 mmol, 1.0 eq.), DIPEA (1.5 mmol, 2.2 eq.) and HATU (0.68 mmol, 0.9 eq.) were dissolved in DMF (3.75 ml) and a solution of ((/?S)-2-cyclopropyl-2-methylamino-ethyl)-carbamic acid tert-butyl ester (0.75 mmol, 1.0 eq.) in DMF (0.4 ml) was added under stirring. The reaction was allowed to stir overnight and the solvent was evaporated. The crude was dissolved in DCM and the organic phase was washed with aq. sat. NaHCOT and dried over Na2S04. The crude product was purified by preparative HPLC yielding the desired product (0.142 g, 50%). LC-MS: tR = 1.00 min; [M+H]' = 416.18. Step 3: (flS)-2-Cyclopropyl-2-[methyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl-ammonium chloride {(flS)-2-Cyclopropyl-2-[methyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl} carbamic acid tert-butyl ester (0.34 mmol, 1.0 eq.) was dissolved in dry MeOH (0.5 ml) and 4M HCI in dioxane (2.0 ml, 30 eq.) was added and the reaction mixture was allowed to stir for 1.5 h. The solvent was evaporated to dryness and the crude product dissolved in MeOH and the mixture was once again evaporated to dryness yielding the product which was used without further purification ioi the next step. Step 4: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {(f?S)-2-[(benzofuran-4-carbonyl)-amlno]-1-cyclopropyl-ethyl}-methyl-amide (/?S)-2-Cyclopropyl-2-[methyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-elhyl-ammonium chloride (0.17 mmol, 1.0 eq.) was suspended in DMF (0.2 ml) and a solution of benzofuran-4-carboxylic acid (0.135 mmol, 0.79 eq.) and DIPEA (0.57 mmol, 3.4 eq.) in DMF (0.54 ml) was added. Finally a solution of HATU (0.135 inl, 0,79 eq.) was added and the mixture was shaken overnight. The solvent was stripped off and the residue was purified by preparative HPLC yielding the desired product (0.0134 g, 22%) LC-MS: tR = 0.99; [M+H]' = 460.18 Examples 2 to 277: The following examples were prepared according to the method given above using the appropriate (2-amino-ethyl)-carbamic acid tert-butyl ester derivative, which was reacted with the appropriate aldehyde in step 1 (in case R2 J H), the appropriate acid A-COOH in step 2, and the appropriate acid R2-COOH in siep 4 to provide the desired final compounds. Example 2: 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxyllc acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-benzyl-amide. LC-MS: to = 1.04 min; [M+H]" = 514.06. Example 3: 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid {2-[(ben20furan-4-carbonyl)-amino]-ethyl}-methyl-amide. LC-MS: tp = 0.92 min; [M+H]' = 438.15. Example 4: 1-Methyl-1W-indazole-3-carboxyllc add (2-{[5-(4-fluoro-p)>enyf)-2-methyl-thiazole-4-carbonyl]-methyl-amlno}-ethyl)-amide. LC-MS: tR = 0.91 min; [M+H]' = 452.18. Example 5: 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid {2-[(2,3-dihydro-benzofuran-7-carbonyl)-amino]-ethyl}-methyl-amide. LC-MS: tR = 0.91 min; [M+H]' = 440.15. Example 6: 6-Methyl-imldazo[2,1-b]thiazole-5-carboxyllc acid (2-{[5-(4-fluoro phenyl)-2-methyl-thiazole-4-carbonyl]-methyl-amino}-ethyl)-amide. LC-MS: tR = 0.75 min; [M+H]' = 458.08. Example 7: 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid benzyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 1.02 min; [M+H]" - 532.16. Example 8: 1-Methyl-1H-indazole-3-carboxylic acid (2-{benzyl-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide. LC-MS: tR = 1.04 min; [M+H]" = 528.18. Example 9: 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid bonzyl-{2-[(2,3-dihydro-benzofuran-7-carbonyl)-amino]-ethyl}-amlde. LC-MS: tR = 1.03 min; [M+H] = 516.18. Example 10: 6-IVIethyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{benzyl-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide. LC-MS: tp - 0.91 min; [M+H]" = 534.14, Example 11: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-(3,3-dimethyl-butyl)-amide. LC-MS: tR = 1.06 min; [M+H]" = 489.21. Example 12: 6-Metfiyl-imidazo[2,1-b]thiiazole-5-carboxylic acid {2-[(3,3-dimethyl-butyl)-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}-amide. LC-MS: tp = 0.94 min; [M+H]' = 509.19. Example 13: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-(3,3-dimethyl-butyl)-amide. LC-MS; tR = 1.05 min; [M+H]" = 507.22. Example 14: 2-Methyl-5-phenyl-thiazole-4-carboxylic add {2-[(ben2ofuran-4-carbonyl)-ammo]-ethyl}-(3-phenyl-propyl)-amide. LC-MS: tR = 1.05 min; [M+H]" = 523.19. Example 15: 6-Methyl-lmida2o[2,1-b]thla2ole-5-carboxylic acid {2-I(2-methyl-5-phenyl-thiazole-4-carbonyl)-(3-phenyl-propyl)-amlno]-ethyl}-amide. LC-MS: tR = 0.92 min; [M+H]" = 543.18. Example 16: 2-Methyl-5-phenyl-thlazole-4-carboxync acid {2-[(2,3-dihydro-benzo[1,4]dloxine-5-carbonyl)-amino]-ethy[}-(3-phenyl-propyl)-amide. LC-MS: tR = 1.04 min; [M+H]' = 541.2. Example 17: 2-Methyl-5-phenyl-thiazole-4-carboxylrc add {2-[(ben/ofuran-4-carbonyl)-amino]-ethyl}-(4-fluoro-benzyl)-amlde. LC-MS: tR = 1.04 min; [M+H]" = 513.15. Example 18: 6-Methyl-imidazot2,1-b]thiazole-5-carboxylic add {2-[(4-fluoro-benzyl)-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 0.91 min; [M+H]" = 533.14. Example 19: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(2,3-dihydro-benzo[1,4]dioxme-5-carbonyl)-amino]-ethyl}-(4-fluoro-benzyl)-amide. LC-MS: tR = 1.02 min; [M+H] = 531.16. Example 20: 2-Methyl-5-phenyl-thiazole-4-carboxylic add {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-phenethyl-amide. LC-MS: tR = 1.04 min; [M+H]" = 509.18. Example 21: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxyllc acid {2-t(2-methyl-5-phenyl-thlazole-4-carbonyl)-phenethyl-amino]-ethyl}-amide. LC-MS: tR = 0.91 min; [M+H] = 529.16. Example 22: 2-Methyl-5-phenyi-thiazole-4-carboxylic add {2-[(2,3-dihydro-benzo[1,4]dloxine-5-carbonyl)-amino]-ethyl}-phenethyl-amlde. LC-MS: tR = 1.04 min; [M+Hf = 527.19. Example 23: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[{benzofuran-4 carbonyl)-amino]-ethyl}-{4-trifluoromethyl-benzyl)-amide. LC-MS: IR - 1.08 min; [M+H]' - 563.15. Example 24: 6-Methyl-imida2o[2,1-b]thiazole-5-carboxylic acid {2-[(2-methyl-5-phenyl-thiazole-4-carbonyl)-(4-trifluoromethyl-benzyl)-amino]-ethyl}-amide. LC-MS: tR = 0.97 min; [M+H]" = 583.13. Example 25: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-(4-trifluoromethyl-benzyl)-amide. LC-MS: tR = 1.06 min; [M+H]' = 581.16. Example 26: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclohexylmethyl-amide. LC-MS: tR = 1.07 min; [M+H]" = 501.21. Example 27: 6-Methyl-imidazo|[2,1-b]thiazole-5-carboxylic acid (2- [cyclohexylmethyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}- amide. LC-MS: tR = 0.94 min; [M+H]" = 521.19. Example 28: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid cyclohexylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 1.06 min; [M+H]" = 519.22. Example 29: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-isobutyl-amide. LC-MS: IR = 1.01 min; [M+H]" = 461.18. Example 30: 6-Methy(-lmfdazo[2,1-b]thiazole-5-carboxyiic acid {2-[isobutyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}-amide. LC-MS: to = 0.86 min; [M+H]" = 481.16. Example 31: 2-Methyl-5-phenyl-thlazole-4-carboxyllc acid {2-[(2,3-dihydro-benzo[1,4]dioxlne-5-carbonyl)-amlno]-ethyl}-isobutyl-amlde. LC-MS: tR = 0.98 min; [M+H]" = 479.19. Example 32: 2-Methyl-5-phenyl-thlazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amlno]-ethyl}-cyclopropylmethyl-amlde. LC-MS: tR = 0,99 min; [M+H]" = 459.16. Example 33: 6-IVIethyl-fmi"da2o[2,1-bIthiazole-5-carboxy(ic acid {2- [cyclopropylmethyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}- amide. LC-MS: tR = 0.84 min; [M+H]' = 479.14. Example 34: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]d[oxine-5-carbonyl)-amino]-ethy(>-amlde. LC-MS: tp = 0.97 min; [M+H]' = 477.17. Example 35: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[{benzofurati-4-carbonyl)-amino]-ethyl}-benzyl-amide. LC-MS: tR = 1.03 min; [M+H]" = 495.16. Example 36: 6-Methyl-imldazo[2,1-b]thiazole-5-carboxylic acid {2-[benzyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}-amlde. LC-MS: tp, = 0.9 min; [M+H]" = 515.14. Example 37: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid benzyl-{2-|i(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide. LC-MS: tp = 1.01 min; [M+H]" = 513.17. Example 38: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-I(benzofuran-4-carbonyl)-amino]-ethyl}-methyl-amide. LC-MS: tn = 0.91 min; [M+H]' = 419.13. Example 39: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[iiieiliyl-{2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}-amide. LC-MS: tp = 0.75 min; [M+H]" = 439.6. Example 40: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-methyl-amide. LC-MS: tp = 0.89 min; [M+H]" = 437.14. Example 41: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amide. LC-MS: tp = 0.96 min; [M+H]" = 445.15. Example 42: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxyllc acid {2-[cyclopropyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}-amlde. LC-MS: tp = 0.8 min; [M+H]" = 465.13. Example 43: 2-Methyl-5-phenyl-thiazole-4-carboxylic add cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 0.93 min; [M+H]' = 463.16. Example 44: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {(RS)-2-[(benzofuran-4-carbonyl)-amlno]-1-cyclopropyl-ethyl}-benzyl-anude. LC-MS: tR = 1.08 min; [M+H]" = 536.19. Example 45: 2-Methyl-5-phenyl-thiazole-4-carboxyllc acid {(RS)-2-[(benzof uran-4-carbonyl)-amino]-1 -cyclopropyl-ethyl}-amide. LC-MS: tR - 0.99 min; [M+H]" = 446.15. Example 46: Benzofuran-4-carboxylic acid {(RS)-2-[(biphenyl-2-carbonyl)-amino]-2-cyclopropyl-ethyl}-amide. LC-MS: tp = 0.98 min; [M+H]" = 425.16. Example 47: 6-Methyl-lmidazo[2,1-b]thiazole-5-carboxylic acid {{RS)-2- cyclopropyl-2-[methyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl} amide. LC-MS: tR = 0.82 min; [M+H]' = 480.18. Example 48: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[benzyl-(2-methy[-5-phenyl-thiazole-4-carbonyl)-amino]-2-cyclopropyl-ethyl}-amide. LC-MS: tR = 0.95 min; [M+H]" = 556.17. Example 49: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-cyclopropyl-2-I(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 0.85 min; [M+H]" = 466.14. Example 50: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[(blphenyl-2-carbonyl)-amino]-2-cyclopropyl-ethyl}-amide. LC-MS: tR = 0.84 min; [M+H]" = 445.17. Example 51: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid ((RS)-1-{[(benzofuran-4-carbonyl)-amino]-methyl}-3-phenyl-propyl)-methyl-amide. LC-MS: tp = 1.07 min; [M+H]" = 524.19. Example 52: 2-Methyl-5-phenyl-thiazole-4-carboxyllc add ((RS)-1-{[(benzofuran-4-carbonyl)-amino]-methyl}-3-phenyl-propyl)-benzyl-amide. LC-MS: tR = 1.14 min; [M+H]" = 600.23. Example 53: 2-Methyl-5-phenyl-thiazole-4-carboxylic aciu uftS)-1-{[(ben2ofuran-4-carbonyl)-amino]-methyl}-3-phenyl-propyl)-amide. LC-MS: tR = 1.07 min; [M+H]' = 510.17. Example 54: Benzofuran-4-carboxylic acid {(RS)-2-[(blphenyl-2-carbonyl)-amino]-4-phenyl-butyl}-amide. LC-MS: tR = 1,05 min; [M+H]" = 489.23. Example 55: 6-Methyl-imida2o[2,1-b]thla20le-5-carboxylic acid {(RS)-2-[methyl-(2-methyl-5-phenyl-thia20le-4-carbonyl)-amino]-4-phenyl-butyl}-amide. LC-MS: tR = 0.93 min; [M+H]" = 544.18. Example 56: 6-IVIethyl-imida2o[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[beinzyi-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-4-plienyl-butyl}-amide. LC-MS: tR = 1.02 min; [M+H]" = 620.22. Example 57: 6-Wlethyl-[mida2o[2,1-bIthlazole-5-carboxy!ic acid {(RS)-2-[(2-methyl-5-phenyl-thla2ole-4-carbonyl)-amino]-4-phenyl-butyl}-amide. LC-MS: tR = 0.95 min; [M+H]" = 530.18. Example 58: 6-Methy[-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[(biphenyl-2-carbonyl)-amino]-4-phenyl-butyl}-amide. LC-MS: tp = 0.94 min; [M+H]" = 509.2. Example 59: 2-Methyl-5-phenyl-thia2ole-4-carboxylic acid {(RS)-2-[(ben20furan-4-carbonyl)-amino]-1-methyl-ethyl}-methyl-amide. LC-MS: tR = 0.93 min; [M+H]" = 434.14. Example 60: 2-Methyl-5-phenyl-thia20le-4-carboxyllc acid {(RS)-2-[(ben2ofuran-4-carbonyl)-amino]-1-methyl-ethyl}-ben2yl-amide. LC-MS: tR = 1.05 min; [M+H]" = 510.13. Example 61: 2-l\/lethyl-5-phenyl-thiazole-4-carboxyllc acid {(RS)-2-[(benzofuran-4-carbonyl)-amino]-1-methyl-ethyl}-amide. LC-MS: tR = 0.95 min; [M+H]" = 420.1. Example 62: Ben20furan-4-carboxylic acid {(RS)-2-[(biphenyi-2-carbony()-amino]-propyl}-amlde, LC-MS: tR = 0.94 min; [M+H]" = 399.12. Example 63: 6-Methyl-lmidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-fbenzyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-propyl}-amide LC-MS: tp = 0.9 min; [M+H]' = 530.16. Example 64: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-propyl}-amide. LC-MS: tp = 0.8 min; [M+H]" = 440.12. Example 65: 6-Methyl-imldazo[2,1-b]thiazole-5-carboxyllc acid {(RS)-2-[(biphenyl-2-carbonyl)-amino]-propyl}-amide. LC-MS: IR = 0.79 min; [M+H]" = 419.13. Example 66: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {(RS)-2-[(benzofuran-4-carbonyl)-amino]-1-benzyl-ethyl}-methyl-amide. LC-MS: IR - 1.04 min; [M+H]' == 510.15. Example 67: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {(RS)-2-[(benzofuran-4-carbonyl)-amlno]-1-benzyl-ethyl}-benzyl-amide. LC-MS: tR - 1.12 min; [M+H]" = 586.2. Example 68: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {(RS)-2-I(benzofuran-4-carbonyl)-amino]-1-benzyl-ethyl}-amide. LC-MS: tp = 1.04 min; [M+H]' = 496.19. Example 69: Benzofuran-4-carboxylic acid {(RS)-2-[(biphenyl-2-carbonyI)-amlno]-3-phenyl-propyl}-amide. LC-MS: tp = 1.03 min; [M+H]' = 475.23. Example 70: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[methyl-(2-methyl-5-phenyl-thlazole-4-carbonyl)-amino]-3-phenyl-propyl}-amide. LC-MS: tR = 0.88 min; [M+H]" = 530.15. Example 71: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[benzyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-3-phenyl-propyl}-amide. LC-MS: tp = 1.01 min; [M+H]" = 606.11. Example 72: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxyllc add {(RS)-2-[(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-3-phenyl-propyl}-amlde. LC-MS: tp = 0.92 min; [M+H]" = 516.16. Example 73: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acm {(RS)-2-[(biphenyl-2-carbonyl)-amino]-3-phenyl-propyl}-amide. LC-MS: tp = 0.91 min; [M+H]" - 495.18. Example 74: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid ((RS)-1-{[(benzofuran-4-carbonyl)-amino]-methyl}-2-methyl-propyl)-methyl-amide. LC-MS: tR = 1 min; [M+H]" = 462.2. Example 75: 2-Methyl-5-phenyl-thlazole-4-carboxylic acid ((RS)-1-{[(benzofuran-4-carbonyl)-amino]-methyl}-2-methyl-propyl) benzyl-amide LC-MS: tR - 1.12 min; [M+H]" = 538.23. Example 76: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid ((RS) 1-{[(benzofuran-4-carbonyl)-amino]-methyl}-2-methyl-propyl)-amide. LC-MS: tp = 1.01 min; [M+H]' = 448.18. Example 77: Benzofuran-4-carboxylic acid {(RS)-2-[(biphenyl-2-carbonyl)-amino]-3-methyl-butyl}-amide. LC-MS: tR = 1 min; [M+H]" = 427.18. Example 78: 6-Methy[-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[benzyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-3-methyl-butyl}-amide. LC-MS: tR - 0.99 min; [M+H]' = 558.1. Example 79: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-3 methyl-2-[(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-butyl}-amide. LC-MS: tR = 0.87 min; [M+H]' = 468.17. Example 80: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[(biphenyl-2-carbonyl)-amino]-3-methyl-butyl}-amide. LC-MS: tR = 0.86 min; [M+H]" = 447.2. Example 81: 2-Methyl-5-phenyl-thiazole-4-carboxy|[c acid ((RS)-1-{[(benzofuran-4-carbonyl)-amino]-methyl}-3-methyl-butyl)-methyl-amide. LC-MS: tp = 1.05 min; [M+H]" = 476.22. Example 82: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid ((RS)-1-{[(benzofuran-4-carbonyl)-amino]-methyl}-3-methyl-butyl)-benzyl-amide. LC-MS: tR = 1.13 min; [M+H]" = 552.22. Example 83: 2-Methyl-5-phenyl-thiazole-4-carboxylic acid ((RS)-1-{[(ben20furan-4-carbonyl)-amino]-methyl}-3-methyl-butyl)-amlde. LC-MS; tR = 1.04 min; [M+H]' = 462.2. Example 84: Benzofuran-4-carboxylic acid {(RS)-2-[(biphenyl-2-carbonyl)-am ino]-4-methyl-pentyl}-amlde. LC-MS: tR = 1.03 min; [M+H]' = 441.21. Example 85: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-4-methyl-2-[methyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-pentyl}-amide. LC-MS: IR = 0.87 min; [M+H]" = 496.19. Example 86: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2 [benzyl-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-4-methyl-penityl}-amlde. LC-MS: tR = 1 min; [M+H]' = 572.22. Example 87: 6-Methyl-imldazo[2,1-b]thiazole-5-carboxylic acid {(RS)-4-methyl-2-[(2-methyl-5-phenyl-thia2ole-4-carbonyl)-amino]-pentyl}-amide. LC-MS: tR = 0.91 min; [M+H]" = 482.19. Example 88: 6-Methyl-lmidazo[2,1-b]thiazole-5-carboxylic acia {(RS)-2-[(biphenyl-2-carbonyl)-amino]-4-methyl-pentyl}-amide. LC-MS: tR = 0.9 min; [M+H]" = 461.21. Example 89: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxyllc acid {(RS)-2-[(blphenyl-2-carbonyl)-methyl-amino]-2-cyclopropyl-ethyl}-amlde. LC-MS: tR = 0.88 min; [M+H]" = 459.2. Example 90: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[(biphenyl-2-carbonyl)-methyi-amino]-4-phenyl-butyl}-amide. LC-MS: tR = 0.97 min; [M+H]" = 523.2. Example 91: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxyllc acid {(RS)-2-[(biphenyl-2-carbonyl)-methyl-amino]-propyl}-amlde. LC-MS: tR = 0.83 min; [M+H]" = 433.14. Example 92: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[(biphenyl-2-carbonyl)-methyl-amino]-3-phenyl-propyl}-amide. LC-MS: tR - 0.92 min; [M+H]" = 509.2. Example 93: 6-Methyl-imida2o[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[(biphenyl-2-carbonyl)-methyl-amino]-3-methyl-butyl}-amide. LC-MS: tR = 0.9 min; [M+H]' = 461.21. Example 94: 6-Methyl-imldazo[2,1-b]thiazole-5-carboxylic acia {(RS)-2-[(blphenyl-2-carbonyl)-methyl-amino]-4-methyl-pentyl}-amide. LC-MS: tR = 0.91 min; [M+H]' = 475.22. Example 95: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic add {(RS)-2-[ben2yl-(biphenyl-2-carbonyl)-amino]-2-cyclopropyl-ethyl}-amide. LC-MS: tp = 0.99 min; [M+H]' = 535.13. Example 96: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[benzyl-(blphenyl-2-carbonyl)-amino]-4-phenyl-butyl}-amide. LC-MS: tR= 1.04 min; [M+H]'= 599.17. Example 97: 6-Methyl-imldazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[ben2yl-(biphenyl-2-carbonyl)-amino]-propyl}-amide. LC-MS: tR = 0.94 min; [M+H]' - 509.2. Example 98: 6-Methyl-imidazo[2,1-b]ttiiazole-5-carboxylic acid {(RS)-2-[benzyl-(biphenyl-2-carbonyl)-amino]-3-plienyl-propyl}-amlde. LC-MS: tR = 1.05 min; [M+H]' = 585.23. Example 99: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {(RS)-2-[benzyl-(biphenyl-2-carbonyl)-amino]-3-methyl-butyl}-amide. LC-MS: IR = 1.03 min; [M+H]' - 537.23. Example 100:6-Methyl-imldazo[2,1-bJthia2Ole-5-carboxylic acid {(RS)-2-[benzyl-(biphenyl-2-carbonyl)-amino]-4-methyl-pentyl}-amide. LC-MS: tR = 1.04 min; [M+H]' = 551.15. Example 101:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic add {2-[cyclopropyl-(2-cyclopropyl-5-phenyl-thiazole-4-carbonyl)-amlno]-ethyl}-amlde. LC-MS: tR = 0.87 min; [M+H]' = 492.18. Example 102:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[cyclopropyl-(2-cyclopropyl-5-m-tolyl-thiazole-4-carbonyl)-amino]-ethyl}-amlde. LC-MS: tp - 0.9 min; [M+H]' = 506.19. Example 103:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{cyclopropyl-[2-cyclopropyl-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-amino}-ethyl)-amide. LC-MS: tR - 0.88 min; [M+H]' := 522.17. Example 104:6-Methyl-imidazo[2,1-b]thlazole-5-carboxylic acid {2-[(2-amino-5-m-tolyl-thiazole-4-carbonyl)-cycropropyl-amino]-ethyl}-amlde. LC-MS; tp = 0.76 min; [M+H]' = 481.18. Example 105:6-Methyl-imldazo[2,1-b]thlazole-5-carboxylic acid (2-{[2-amino-5 (3-fluoro-phenyl)-thiazole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amide. LC-MS: tR = 0.75 min; [M+H]' = 485.16. Example 106:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[2-amino-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amide. LC-MS: tR - 0.74 min; [M+H]' = 497.17. Example 107:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[2-amino-5-(4-fluoro-phenyl)-thiazole-4-carbonyl]-cyclopropyl-ammo}-ethyl)-amlde. LC-MS: tR = 0.74 min; [M+H]' - 485.17. Example 108:6-Methyl-imidazo[2,1-b]thia2ole-5-carboxylic acid (2-{[2-amino-5-(3-chloro-phenyl)-thia2ole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amide. LC-MS: tp = 0.78 min; [M+H]' = 500.53. Example 109:6-Methyl-imidazo[2,1-b]thia2ole-5-carboxylic acid {2-[(2-amino-5-phenyl-thiazole-4-carbonyl)-cyclopropyl-amino]-ethyl}-amide. LC-MS: tp = 0.73 min; [M+H]' = 467.17. Example 110:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[2-bromo-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-cyclopropyl-amlno}-ethyl)-amide. LC-MS: tR = 0.88 min; [M+H]' = 560.05. Example 111: 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylicacid{2-[(2-bromo-5-p-toIyN thiazole-4-carbonyl)-cyclopropyl-amino]-ethyl}-amlde. LC-MS: tR = 0.9 min; [M+H]' = 546.07. Example 112:6-Methyl-imidazo[2,1-b]thiazole-5-carboxyllc acid {2-{cyclopropyl-[5-(2-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide. LC-MS: tR = 0.82 min; [M+H]' = 484.16. Example 113:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{cyclopropyl- [2-methyl-5-(3-trifluoromethyl-phenyl)-thia2ole-4-carbonyl]-amino}-ethyl)- amide. LC-MS: tR =: 0.89 min; [M+H] = 534.08. Example 114:6-Methyl-imldazo[2,1-b]thiazole-5-carboxylic acid (2-{cyclopropyl-[5-(3-fluoro-phenyl)-2-methyl-thlazole-4-carbonyl]-amino}-ethyl) amide. LC-MS: tR = 0.82 min; [M+H]* = 484.17. Example 115:6-Methyl-lmidazo[2,1-b]thlazole-5-carboxylic acid (2-{cyclopropyt-[2-methyl-5-(4-trifluoromethyl-phenyl)-thia2ole-4-carbonyl]-amino) ethyl)-amide. LC-MS: tp - 0.89 min; [M+H]' = 534.09. Example 116:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{t5-(4-chloro-phenyl)-2-methyl-thla2ole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amlde. LC-MS: tR = 0.85 min; [M+H]* = 499.99. Example 117:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic add (2-{cyclopropyl-[5-(3-methoxy-phenyl)-2-methyl-thlazole-4-carbonyl]-amlno}-ethyl)-amlde. LC-MS: tp = 0.82 min; [M+H]' = 496.18. Example 118:6-Methyl-lmidazo[2,1-b]thia2ole-5-carboxyllc acid (2-{[5-(3-cyano-phenyl)-2-methyl-thiazole-4-carbonyl]-cyclopropyl-ai))ino|-ethyi)-ci(riide. LC-MS: tR = 0.8 min; [M+H]" = 491.17. Example 119:6-MethyMmidazo[2,1-b]thia20le-5-carboxylic acid (2-{cyclopropyI-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amlde. LC-MS: tp = 0.87 min; [M+H]" = 494.19. Example 120:6-Methyl-imidazo[2,1-b]thiazole-5-carboxyllc acid {2-[cyclopropyl-(2-methyl-5-/j-tolyl-thiazole-4-carbonyl)-amino]-ethyl}-amJde. LC-MS: tR = 0.84 min; [M+H]" = 480.19. Example 121:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[cyclopropyl-(3'-methyl-biphenyl-2-carbonyl)-ammo]-ethyl}-amide. LC-MS: tR = 0,9 min; [M+H]" = 459.23. Example 122:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[cyclopropyl-(4'-methyl-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 0.91 min; [M+H]' = 459.22. Example 123:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[cyclopropyl (4'-fluoro-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 0.88 min; [M+H]" - 463.2. Example 124:1-Methyl-1W-lndazole-3-carboxylic acid {2-[cyclopropyl-(2-cyclopropyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}-amide. LC-MS; tp = 1.01 min; [M+H]' = 486.22. Example 125:1-Methyl-1H-indazole-3-carboxylic acid {2-[cyclopropyl-(2-cyclopropyl-5-/r7-tolyl-thiazole-4-carbonyl)-amino]-ethyl}-amlde. LC-MS: tR = 1.04 min; [M+H]' = 500.15. Example 126:1-Methyl-1W-Jndazole-3-carboxylic acid (2-{cyclopropyl-[2-cyclopropyl-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-amino}-elhyl)-amide. LC-MS: tR = 1.02 min; [M+H]' = 516.22. Example 127:1-l\/lethyl-1W-indazole-3-carboxylic acid {2-[(2-amino-5-m-tolyl-thiazole-4-carbonyl)-cyclopropyl-amino]-ethyl}-amide. LC-MS; IR = 0.88 min; [M+H]' = 475.23. Example 128:1-Methyl-1W-indazole-3-carboxylic add (2-{[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amide. LC-MS: tR = 0.88 min; [M+H]' = 479.2. Example 129:1-Methyl-1W-indazole-3-carboxylic acid (2-{[2-amino-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-cyclopropyl-amlno}-ethyl)-amlde. LC-MS; IR = 0.87 min; [M+H]' = 491.21. Example 130:1-Methyl-1W-indazole-3-carboxylic acid (2-{[2-amino-5-(4-fluoro-phenyl)-thiazole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amide. LC-MS: tR = 0.87 min; [M+H]' = 479.2. Example 131:1-Methyl-1W-indazole-3-carboxylic acid (2-{[2-amino-5-(3-cliloro-piienyl)-thiazole-4-carbonyl]-cyclopropyl-amino}-etfiyl)-amide. LC-MS: tR = 0.91 min; [M+H]' = 495.17. Example 132:1-JVIethyl-1H-indazole-3-carboxylic acid {2-[(2-aniino-5-phenyl-thiazole-4-carbony()-cyclopropyl-amino]-ethyl}-amide. LC-MS: tR = 0.86 min; [M+H]' = 461.22. Example 133:1-Methyl-1W-indazole-3-carboxylic acid (2-{[2-bromo-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amide. LC-MS; tp = 1.02 min; [M+H]' = 554.1. Example 134:1-Methyl-1H-indazole-3-carboxylic acid {2-|i(2-bromo-b-p-lolyl-thiazole-4-carbonyl)-cyclopropyl-amino]-ethyl}-amide. LC-MS: tp = 1.04 min; [M+H]" = 538.11. Example 135:1-Methyl-1W-indazole-3-carboxylic acid (2-{cyclopro|)yl-[5-(2-fluoro-piienyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide. LC-MS: tR = 0.96 min; [M+H]' = 478.2. Example 136:1-IVIethyl-1H-indazole-3-carboxyllc acid (2-{cyclopropyl-[2-methyl-5-(3-trifluoromethyl-plienyl)-thiazole-4-carbonyl]-amino}-ethyl)-amide. LC-MS: tR = 1.01 min; [M+H]' = 528.18. Example 137:1-Methyl-1W-indazole-3-carboxylic acid (2-{cyclopropyl-[5-(3-fluoro-phenyl)-2-metiiyl-thiazole-4-carbonyl]-amino}-ethyl)-amide. LC-MS: tR = 0.96 min; [M+H]' = 478.2. Example 138:1-Methyl-1W-indazole-3-carboxylic acid (2-{cyclopropyl-[2-methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-ethyl)-amide. LC-MS: tR= 1.02 min; [M+H]'= 528.16. Example 139:1-Methyl-1W-indazole-3-carboxylic acid (2-{[5-(4-chloro-phenyl)-2-metiiyl-thiazole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amide. LC-MS: tR = 0.99 min; [M+H]' = 494.16. Example 140:1-Methyl-1W-indazole-3-carboxylic acid (2-{cyclopropyl-[5-(3-methoxy-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethy()-amide. LC-MS: tR = 0.96 min; [M+H]' = 490.22. Example 141:1-Methyl-1H-lndazole-3-carboxy[ic acid (2-{[5-(3-cyano-phenyl)-2-methyl-thiazole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amide. LC-MS: tR = 0.93 min; [M+H]' = 485.2. Example 142:1-IVIethyl-1H-indazole-3-carboxylic acid (2-{cyclopropyl-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyi) amide. LC-MS: tn = 1.01 min; [M+H] = 488.23. Example 143:1-Methyl-1H-indazole-3-carboxylic acid {2-icyclopropyl-(2-methyl-5-p-tolyl-thiazole-4-carbonyl)-amino]-ethyl}-amide. LC-MS: tR - 0.98 min; [M+H]" = 474.23. Example 144:1-Methyl-1H-indazole-3-carboxylic acid {2-[cyclopropyl-(3'-methyl-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS: tR - 1.03 min; [M+H]' = 453.25. Example 145:1-l\/lethyl-1H-indazole-3-carboxylic acid {2-[cyclopropyl-{4'-methyl-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS; tR = 1.03 min; [M+H]' = 453.27. Example 146:1-Methyl-1W-indazole-3-carboxylic acid {2-[cyclopropyl-(4'-fluoro-biphenyl-2-carbonyl)-amino]-etliyl}-amide. LC-MS: tR = 1 min; [M+H]' = 457.24. Example 147:2-Cyclopropyl-5-phenyl-thia2ole-4-carboxylic acid {2-[(ben20furan-4-carbonyl)-amino]-etliyl}-cyclopropyl-amide. LC-MS: tR = 1.01 min; [M+H]' = 472.22. Example 148:2-Cyclopropyl-5-n7-tolyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amlde. LC-MS: tR = 1.04 min; [M+H]' = 486.21. Example 149:2-Cyclopropyl-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amtno]-ethyl}-cyclopropyl-amlde. LC-MS: tR=: 1.02 min; [M+H]" = 502.12. Example 150:2-Amino-5-/n-tolyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amide. LC-MS; tp = 0.88 min; [M+H]" = 461.19. Example 151:2-Amlno-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amide. LC-MS: tR = 0.88 min; [M+H]" = 465.18. Example 152:2-Amino-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amJde. LC-MS: tR = 0.87 min; [M+H]' = 477.19. Example 153:2-Amino-5-(4-fluoro-phenyl)-thlazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-aminol-ethyl}-cyclopropyl-amide. LC-MS: tp - 0.87 min; [M+H] - 465.18. Example 154:2-Amlno-5-(3-chloro-phenyl)-thiazole-4-carboxyllc acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amide. LC-MS: tR = 0.91 min; [M+H]' = 481.14. Example 155:2-Amino-5-phenyl-thiazole-4-carboxyllc acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amide. LC-MS: IR = 0.85 min; [M+H]' = 447.18. Example 156:2-Bromo-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amide. LC-MS: tR = 1.02 min; [M+H]' = 540.08. Example 157:2-Bromo-5-p-tolyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amide. LC-MS: tR = 1.04 min; [M+H]" = 524.06. Example 158:5-(2-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amide. LC-MS: tR = 0.96 min; [M+H]' = 464.18. Example 159:2-Methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amide. LC-MS: tR = 1.01 min; [M+H]'' = 514.14. Example 160:5-(3-Fluoro-phenyl)-2-methyl-thiazole-4-carboxyllc acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amide. LC-MS: tR = 0.97 min; [M+H] = 464.18. Example 161:2-Methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amlde. LC-MS: tR = 1.02 min; [M+H]'= 514.14. Example 162:5-(4-Chloro-phenyl)-2-methyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amide. LC-MS: tfi - 0.99 min; [M+H]' = 480.15. Example 163:5-(3-Methoxy-phenyl)-2-methyl-thlazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amide. LC-MS: tR = 0.96 min; [M+H]' = 476.19. Example 164:5-(3-Cyano-phenyl)-2-methyl-thiazole-4-carboxylic acid {2 [(benzofuran-4-carbonyl)-amino]-ethyl}-cyc[opropyl-amide. LC-MS; tR = 0.94 min; [M+H]" = 471.18. Example 165:5-(3,4-Dimethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amrno]-ethyl}-cyclopropyl-amide. LC-MS: tR - 1.01 min; [M+H]' = 474.22. Example 166:2-Methyl-5-p-tolyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyl-amlde. LC-MS: tR = 0.99 min; [M+H]" = 460.19. Example 167: Benzofuran-4-carboxylic acid {2-[cyclopropyl-(3-methyl-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS: tR - 1.03 min; [M+H]" = 439.21. Example 168:Benzofuran-4-carboxylic acid {2-[cyclopropyl-(4'-methyl-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 1.03 min; [M+H]" = 439.22. Example 169:Benzofuran-4-carboxylic acid {2-[cyclopropyl-(4'-fluoro-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 1 min; [M+H]" = 443.2. Example 170:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2- [cyclopropyImethyl-(2-cyclopropyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}- amide. LC-MS: tR = 0.9 min; [M+H]" - 506.17. Example 171:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2- [cyclopropylmethyl-(2-cyclopropyl-5-/77-tolyl-thiazole-4-carbonyl)-amlno]-ethyl}- amide. LC-MS; tR = 0.94 min; [M+H]' = 520.2. Example 172:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[2- cyclopropyl-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-cyclopropylmethyl- amino}-ethyl)-amide. LC-MS: tR = 0.91 min; [M+H]' = 536.19. Example 173:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic add {2-[(2-amino-5-m-tolyl-thlazole-4-carbonyl)-cyclopropylmethyl-amino]-ethyl}-amide. LC-MS: tp = 0.8 min; [M+H]' = 495.2. Example 174:6-Methyl-lmidazo[2,1-b]thlazole-5-carboxylic acid (2-{I2-amlno-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-cyclopropylmethyl-amino}-ethv!)-amide. LC-MS: tR - 0.79 min; [M+H]' = 499.15. Example 175:6-IVIethyl-lmidazo[2,1-b]thiazole-5-carboxyllc acid (2-{[2 amino-5- (3-methoxy-phenyl)-thlazole-4-carbonyl]-cyclopropylmethyl-amino}-ethyl)- amide. LC-MS: tR = 0.77 min; [M+H]" = 511.07. Example 176:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[2-amino-5-(4-fluoro-phenyl)-thiazole-4-carbonyl]-cyclopropylmethyl-amino}-ethyl)-amide. LC-MS: IR = 0.78 min; [M+H]" = 499.18. Example 177:6-Methyl-lmldazo[2,1-b]thiazole-5-carboxyllc acid (2-{[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyij-cyciopropyimethyl-amino} ethyl) amide LC-MS: tR = 0.81 min; [M+H]" = 515.12. Example 178:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[(2-amino-5-phenyl-thiazole-4-carbonyl)-cyclopropylmethyl-amino]-ethyl}-am[de. LC-MS: tR = 0.77 min; [M+H]" = 481.17. Example 179:6-Methyl-imidazo[2,1-b]thiazole-5-carboxyllc acid (2-{[2-bromo-5- (3-methoxy-phenyl)-thiazoIe-4-carbonyl]-cyclopropylmethyl-amino}-ethyl)- amide. LC-MS: tR = 0.89 min; [M+H]" = 574.04. Example 180:6-Methyl-lmidazo[2,1-b]thiazole-5-carboxylic acid {2-[(2-bromo-5-p-tolyl-thiazole-4-carbonyl)-cyclopropylmethyl-amino]-ethyl}-amide. LC-MS: tR = 0.91 min; [M+H]" = 558.04. Example 181:6-Methyl-imldazot2,1-b]thiazole-5-carboxylic acid (2- {cyclopropylmethyl-[5-(2-fluoro-phenyl)-2-methyl-thiazole-4-carbonylJ-amino}- ethyl)-amide. LC-MS: tR = 0.86 min; [M+H]' = 498.16. Example 182:6-Methyl-imidazoi;2,1-b]thla2ole-5-carboxylic acid (2 {cyclopropylmethyl-[2-methyl-5-(3-trlfluoromethyl-phenyl)-thia20le-4-carbonyl]- amino}-ethyl)-amide. LC-MS: tR = 0.92 min; [M+H]" = 548.15. Example 183:6-Methyl-imidazo[2,1-b]thlazole-5-carboxylic acid (2- {cyclopropylmethyl-[5-(3-fluoro-phenyl)-2-methyl-thlazole-4-carbonyl]-amlno}- ethyl)-amide. LC-MS: tR = 0.86 min; [M+H]' = 498.17. Example 184:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2- {cyclopropylmethyl-[2-methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]- amino}-ethyl)-amide. LC-MS: tR = 0.92 min; [M+H]' - 548.15. Example 185:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[5-{4-chloro-phenyl)-2-methyl-thiazole-4-carbonyl]-cyclopropylmethyi-amino}-ethyl)-amide. LC-MS: tR = 0.88 min; [M+H]" = 514.13. Example 186:6-IWethyl-imidazo[2,1-b]th[azole-5-carboxyllc acid (2- {cyclopropylmethyl-[5-(3-methoxy-phenyl)-2-methyl-thiazole-4-carbonyl]- amino}-ethyl)-amide. LC-MS: tR = 0.85 min; [M+H]" = 510.13. Example 187:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[5-{3-cyano-phenyl)-2-methyl-thiazole-4-carbonyl]-cyclopropylmethyl-amino}-ethyl)-amide. LC-MS: tR = 0.83 min; [M+H]" = 505.16. Example 188:6-Methyl-lmldazo[2,1-b]thiazole-5-carboxylic acid (2- {cyclopropylmethyl-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carbonyl]- amino}-ethyl)-amide. LC-MS: tR = 0.9 min; [M+H]" = 508.2. Example 189:6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2- [cyclopropylmethyl-(2-methyl-5-p-tolyl-thiazole-4-carbonyl)-amino]-ethyl}- amide. LC-MS: tR = 0.88 min; [M+H]' = 494.2. Example 190:6-Methyl-imidazof2,1-b]thiazole-5-carboxylic acid {2-[cyclopropylmethyl-(3'-methy[-blphenyl-2-carbonyl)-aminoJ-ethyl}-amide. LC-MS: tR = 0.93 min; [M+H]' = 473.23. Example 191:6-Methyl-lmldazo[2,1-b]thlazole-5-carboxylic acid {2-[cyclopropylmethyl-(4'-methyl-biphenyl-2-carbonyl)-amino]-ethyl} aiiude. LC-MS: tR = 0.91 min; [M+H]' = 473.23. Example 192:1-l\fletiiyl-1W-indazole-3-carboxylic acid {2-[cyclopropylmethyl-(2-cyclopropyl-5-phenyl-thiazole-4-carbonyl)-amino]-etiiyl}-amide. LC-MS: tR = 1.04 min; [M+H]' = 500.07. Example 193:1-Metfiyl-1H-indazole-3-carboxylic acid {2-[cyclopropyImethyl-(2-cyclopropyl-5-m-tolyl-thiazole-4-carbonyl)-amino]-etliyl}-amide. LC-MS: tR = 1.07 min; [M+H]' = 514.25. Example 194:1-Methyl-1H-indazole-3-carboxylic acid (2-t[2-cyclopropyl-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-cyclopropylmethyl-amino}-ethyl)-amide. LC-MS: tR = 1.04 min; [M+H]' = 530.24. Example 195:1-Methyl-1H-indazole-3-carboxylic acid {2-[(2-amino-5-m-tolyl-thiazole-4-carbonyl)-cyclopropylmethyl-amino]-ethyl}-amJde. LC-MS: tR - 0.92 min; [M+H]' = 489.23. Example 196:1-Metiiyl-1W-indazole-3-carboxylic acid (2-{[2-amino-5-(3-fluoro-phenyl)-thiazole-4-carbonyl]-cyclopropylmethyl-amlno}-ethyl)-amide. LC-MS: tR = 0.92 min; [M+H]' = 493.2. Example 197:1-IVIethyl-1W-indazole-3-carboxylic acid (2-{[2-amino-5-(3-methoxy-plienyl)-thiazole-4-carbonyl]-cyclopropylmetiiyl-amino>-ethyl)-amide. LC-MS: tR = 0.9 min; [M+H]' = 505.22. Example 198:1-Methyl-1W-indazole-3-carboxylic acid (2-{[2-amino-5-(4-fluoro-plienyl)-thiazole-4-carbony[]-cyclopropylmethyl-amino}-ethyl)-amide. LC-MS: tfl = 0.91 min; [M+H]' = 493.2. Example 199:1-Methyl-1H-indazole-3-carboxylic acid (2-{[2-amino-5-(3-chloro-phenyl)-thiazole-4-carbonyl]-cyclopropylmethyl-amino}-ethyl)-amide. LC-MS: tp = 0.95 min; [M+H]' = 509.17. Example 200:1-Methyl-1H-indazole-3-carboxylic acid {2-[(2-amino-5-phenyl-thiazole-4-carbonyl)-cyclopropylmethyl-amino]-ethyl}-amide. LC-MS: tR = 0.89 min; [M+H]" = 475.23. Example 201:1-[yiethyl-1W-indazole-3-carboxylic acid (2-{[2-bromo-5-(3-methoxy-phenyl)-thiazole-4-carbonyl]-cyclopropylmethyl-ammo}-ethyl)-amrde LC-MS: tR = 1.04 min; [M+H]" = 570.12. Example 202:1-Methyl-1H-indazole-3-carboxylic acid {2-[(2-bromo-5-p luiyl-thiazole-4-carbonyl)-cyciopropylmethyl-amino]-ethyl}-amide. LC-MS: tR = 1.06 min; [M+H]' = 554.11. Example 203:1-IV!ethyl-1H-indazole-3-carboxylrc acid (2-{cyclopropylinethyl-[5-(2-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide. LC-MS: tR = 1 min; [M+H]' - 492.2. Example 204:1-Methyl-1H-indazole-3-carboxylic acid (2-{cyclopropyimetliyl-[2-methyl-5-(3-trifluorometliyl-phenyl)-thiazole-4-carbonyl]-amino}-ethiyl)-amide. LC-MS: tp = 1.05 min; [M+H]" = 542.11. Example 205:1-Methyl-1H-indazole-3-carboxylic acid (2-{cyclopropvlmethyl-lb-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide. LC-MS: tp - 0.99 min; [M+H]' - 492.21. Example 206:1-Methyl-1//-indazole-3-carboxylic acid (2-{cyclopropylmethyl-[2-methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino>-ethyl)-amlde. LC-MS: tR = 1.04 min; [M+H]" = 542.12. Example 207:1-Methyl-1W-indazole-3-carboxylic acid (2-{15-(4-chloro-phenyl)-2-methyl-thiazole-4-carbonyi]-cyclopropylmethyl-amino}-ethyl)-amide. LC-MS: tp = 1.02 min; [M+H]" = 508.18. Example 208:1-Methyl-1H-indazole-3-carboxyllc acid (2-{cyciopropylmethyi-[5-(3-methoxy-plienyl)-2-methyl-tliiazole-4-carbonyl]-amino}-ethyl)-amide. LC-MS: tR = 0.99 min; [M+H]" = 504.22. Example 209:1-MethyMW-indazole-3-carboxylJc acid (2-{[5-(3-cyano-phenyl)-2-methyl-thlazole-4-carbonyl]-cyclopropylmethyl-amino}-ethyl)-amidG. LC-MS: tR = 0.97 min; [M+H]' = 499.24. Example 210:1-Methyl-1H-indazole-3-carboxylic acid (2-{cycIopropylmethyl-[5 (3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide. LC-MS: tR = 1.03 min; [M+H]" = 502.16. Example 211:1-MethyI-1W-indazole-3-carboxylic acid {2-fcyclopropyimethyl-(2-methyl-5-p-tolyl-thiazole-4-carbonyl)-amino]-ethyl}-amide. LC-MS: IR = 1.01 min; [M+H]" = 488.24. Example 212:1-Methyl-1W-lndazole-3-carboxylic acid {2-[cyclopropylmethyl-(3'-methyl-biphenyl-2-carbonyl)-amino]-etliyl}-amide. LC-MS: tR = 1.06 min; [M+H]' = 467.27. Example 213:1-Methyl-1H-indazole-3-carboxylic acid {2-[cyclopropylmethyl-(4'-methyl-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 1.06 min; [M+H]" = 467.27. Example 214:1-Methyl-1H-indazole-3-carboxylic acid {2-[cyclopropylmethyl-(4'-fluoro-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS: tp = 1.04 min; [M+H]" = 471.25. Example 215:2-Cyclopropyl-5-phenyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 0.99 min; [M+H]" = 490.2. Example 216:2-Cyclopropyl-5-m-tolyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-diliydro-benzo[1,4]dioxine-5-carbonyl)-ammo]-ethyl}-amide. LC-MS: tR = 1.02 min; [M+H]" = 504.22. Example 217:2-Cyclopropyl-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}- amide. LC-MS: tR = 1 min; [M+H]" = 520.21. Example 218:2-Amino-5-m-tolyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 0.86 min; [M+H]" = 479.21. Example 219:2-Amino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic aciu cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbofiyl)-amino] ethyl}-amide. LC-MS: IR = 0.87 min; [M+H]' = 483.18. Example 220:2-Amlno-5-(3-methoxy-phenyl)-thiazole-4-carboxyIic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-ammo]-ethyl}- amide. LC-MS: tR = 0.85 min; [M+H]' = 495.19. Example 221:2-Amino-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}- amide. LC-MS: tp = 0.85 min; [M+H]' = 483.19. Example 222:2-Amino-5-(3-chloro-phenyl)-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-am[no]-ethyl}- amtde. LC-MS: IR = 0.89 min; [M+H]' = 499.21. Example 223:2-Amlno-5-phenyl-thiazole-4-carboxylic acid cyclopKjpyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide. LC-MS: IR = 0.84 min; [M+H]' - 465.2. Example 224; 2-Bromo-5-(3-methoxy-phenyl)-thiazole-4-carboxyllc acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}- amide. LC-MS: tR = 1.01 min; [M+H]" = 558.05. Example 225:2-Bromo-5-p-tolyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amlde. LC-MS: tR = 1.03 min; [M+H]" = 542.04. Example 226:5-(2-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dloxine-5-carbonyl)-amlno]-ethyl}- amide. LC-MS: IR = 0.94 min; [M+H]" = 482.18. Example 227:2-Methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxyllc acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxme-5-carbonyl)-amino]-ethyl}- amide. LC-MS: tfi = 1 min; [M+H]' = 532.17. Example 228:5-(3-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dloxine-5-carbonyl)-amino]-ethyl}- amide. LC-MS: tR = 0.95 min; [M+H]" = 482.18. Example 229:5-(4-Chloro-phenyl)-2-methyl-thiazole-4-carboxyllc acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}- amide. LC-MS: tR = 0.98 min; [M+H]' = 498.15. Example 230:5-(3-Methoxy-phenyl)-2-methyl-thlazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}- amide. LC-MS: tR = 0.94 min; [M+H]" = 494.2. Example 231:5-(3,4-Dimethyl-phenyl)-2-methyl-thlazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]d[oxine-5-carbonyl)-amino]-ethyl}-amide. LC MS: tn = 0.99 min; [M+H]' = 492.23. Example 232:2-Methyl-5-p-tolyl-thiazole-4-carboxyllc acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide. LC-MS; tR = 0.97 min; [M+H]' = 478.21. Example 233:2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid {2-|;cyclopropyl-(3'-methyl-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 1 min; [M+H]' = 457.25. Example 234:2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid {2-[cyclopropyl-(4'-methyl-biphenyl-2-carbonyl)-amlno]-ethyl}-amlde. LC-MS: tR = 1.01 min; [M+H]" = 457.24. Example 235:2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid {2-[cyclopropyl-(4'-fluoro-blphenyl-2-carbonyl)-amino]-ethyl}-amlde, LC-MS: tp = 0.98 min; [M+H]' = 461.22. Example 236:2-Cyclopropyl-5-phenyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxlne"5-carbonyl)-amino]- ethyl}-amide. LC-MS: tR = 1.02 min; [M+H]' = 504.2. Example 237:2-Cyclopropyl-5-m-tolyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-ben20[1,4]dioxJne-5-carbonyl)-amino]- ethyl}-amide. LC-MS: tR = 1.05 min; [M+H]' = 518.15. Example 238:2-Cyclopropyl-5-(3-methoxy-phenyl)-thiazole-4-carboxyllc acid cyclopropy[methyl-{2-[(2,3-dihydro-benzo[1,4]diox[ne-5-carbony!)-amino]- ethyl}-amide. LC-MS: tR = 1.03 min; [M+H]' = 534.13. Example 239:2-Amino-5-/n-tolyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 0.9 min; [M+H]" = 493.21. Example 240:2-Amlno-5-(3-fluoro-phenyl)-thia2ole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dloxine-5-carbonyl)-amino]- ethyiy-amide, LC-MS: tR - 0.91 min; [M-i H]" = 497.17. Example 241:2-Amino-5-(3-methoxy-phenyl)-thiazo!e-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dloxine-5-carbonyl)-amino]- ethyl}-amide. LC-MS: tR = 0.9 min; [M+H]" = 509.19. Example 242:2-Amino-5-phenyl-thlazole-4-carboxyllc acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amlnoj-ethyl}-amide. LC-MS: tp = 0.9 min; [M+H]" = 479.2. Example 243:2-Bromo-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxlne-5-carbonyl)-amino]- ethyl}-amide. LC-MS: tR = 1.03 min; [M+H]" = 572.09. Example 244:2-Bromo-5-p-tolyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amlde LC-MS: tR = 1.06 min; [M+H]' = 556.09. Example 245:5-(2-Fluoro-phenyl)-2-methyl-thia2ole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxlne-5-carbonyl)-amino]- ethyl}-amide. LC-MS: tR = 0.98 min; [M+H]' - 496.18. Example 246:2-Methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dloxme-5-carbonyl)-amino]- ethyl}-amrde. LC-MS: tR = 1.03 min; [M+H]' = 546.17. Example 247:5-(3-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amlno]- ethyl}-amide. LC-MS: tR = 0.98 min; [M+H]" = 496.18. Example 248:5-(3-Methoxy-phenyl)-2-methyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amlno]- ethyl}-amide. LC-MS: tR = 0.97 min; [M+H]' = 508.19. Example 249:5-{3-Cyano-pheny!)-2-methyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-am[no]- ethyl}-amide. LC-MS: tR = 0.95 min; [M+H]" = 503.09. Example 250:5-(3,4-Dimethyl-phenyl)-2-methyl-thlazole-4-carboxyllc acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dJoxine-5-carbonyl)-amino]- ethyl}-amide. LC-MS: tR = 1.02 min; [M+H]" = 506.22. Example 251:2-Methyl-5-p-tolyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amlno]-ethyl}-amide. LC-MS: tR = 1 min; [M+H]" = 492.22. Example 252:2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid {2-[cyclopropylmethyl-(3'-methyl-biphenyl-2-carbonyl)-aminoI-ethyl}-amlde. LC-MS: tR = 1.03 min; [M+H]' = 471.25. Example 253:2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid {2-[cyclopropylmethyl-(4-methyl-biphenyl-2-carbonyl)-aminoJ-ethyl}-amide. LC-MS: IR = 1.04 min; [M+H]' = 471.25. Example 254:2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid {2-[cyclopropylmethyl-(4'-fluoro-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS: tp = 1.02 min; [M+H]" = 475.24. Example 255:2-Cyclopropyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-amlde. LC-MS: tp = 1.04 min; [M+H]'= 486.2. Example 256:2-Cyciopropyl-5-m-tolyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amlno]-ethyl}-cyclopropylmethyl-amide. LC-MS: tn = 1.06 min; [M+H]" = 499.93. Example 257:2-Cyclopropyl-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-am[de. LC-MS: tp = 1.04 min; [M+H]" = 516.2. Example 258:2-Amino-5-/r7-tolyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-elhyl}-cyclopropylmethyl-amide. LC-MS: tn - 0.92 min; [M+H]" = 475.21. Example 259:2-Amlno-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-amide. LC-MS: tR = 0.92 min; [M+H]" = 479.18. Example 260:2-Amino-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-ammo]-ethyl}-cyclopropylmethyl-amide. LC-MS: tp = 0.9 min; [M+H]" = 491.19. Example 261:2-Amlno-5-(4-fluoro-phenyl)-th(azole-4-carboxyllc add {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-amide. LC-MS: tp = 0.91 min; [M+H]" = 479.18. Example 262:2-Amino-5-(3-chloro-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-amlde. LC-MS: tp = 0.95 min; [M+H]' = 495.14. Example 263:2-Amino-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-amide, LC-MS; tR = 0.89 min; [M+H]" = 461.19. Example 264:2-Bromo-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl amide, LC-MS: tp = 1.05 min; [M+H]' = 556.07. Example 265:2-Bromo-5-p-tolyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropyimethyl-amlde. LC-MS: tp = 1.07 min; [M+H] = 540.08. Example 266:5-(2-Fluoro-phenyl)-2-methyl-thJazole-4-carboxync acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-arnide. LC~MS: tR = 1 min; [M+H]" = 478.17. Example 267:2-Methyl-5-(3-trifluoromethyl-phenyl)-thia2ole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethy(}-cyclopropyln\ethyi-amide. LC-MS: IR = 1.04 min; [M+H]" = 528.16. Example 268:5-(3-Fluoro-phenyl)-2-methyl-thia2ole-4-carboxylic acid (2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-amlde. I C-MS: tp = 1 min; [M+HV = 478.19. Example 269:2-Methyl-5-(4-trifluoromethyl-phenyl)-thlazole-4-carboxylic acid {2-[(ben20furan-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-amide. LC-MS: tR=: 1.05 min; [M+H]" = 528.16. Example 270:5-(4-Chloro-phenyl)-2-methyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-amide. LC-MS: tR=: 1.02 min; [M+H]" = 494.15. Example 271:5-(3-Methoxy-phenyl)-2-methyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-amide. LC-MS: tR = 1 min; [M+H] = 490.22. Example 272:5-(3-Cyano-phenyl)-2-methyl-thiazole-4-carboxylic acid {2-[(benzcfuran-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-amlde. LC-MS; tR = 0.95 min; [M+H] = 485.18. Example 273:5-(3,4-Dimethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid {2-[(ben20furan-4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-amide. LC-MS: tR - 1.04 min; [M+H]' - 488.22. Example 274:2-IVIethy[-5-p-tolyl-thiazole-4-carboxylic acid {2-[(benzofuran 4-carbonyl)-amino]-ethyl}-cyclopropylmethyl-amide. LC-MS: tR = 1.02 min; [M+H] = 474.22. Example 275: Benzofuran-4-carboxylic acid {2-[cyclopropylmethyl-(3'-methyl-biphenyl-2-carbonyl)-amino]-etiiyl}-amide. LC-MS: tR = 1.05 min; [M+H]' = 453.25, Example 276: Benzofuran-4-carboxylic acid {2-[cyclopropylmethyl'(4'-meihyl-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 1.05 min; [M+H]' = 453.25. Example 277: Benzofuran-4-carboxylic acid {2-[cyclopropylmethyl-(4'-fluoro-biphenyl-2-carbonyl)-amino]-ethyl}-amide. LC-MS: tR = 1.01 min; [M+H]" = 457.22. II. Biological assays In vitro assay The orexin receptor antagonistic activity of the compounds of turmula (1) is determined in accordance with one of the following experimental metliuds. Experimental method: Chinese hamster ovary (CHO) cells expressing the human orexin-1 receptor and the human orexin-2 receptor, respectively, are grown in culture medium (Ham F-12 with L-Glutamine) containing 300 |ag/ml G418, 100 U/ml penicillin, 100 Mid/i"i stiuplornycin and 10 % heat inactivated fetal calf serum (FCS). The cells are seeded at 20'000 cells / well into 384-well black clear bottom sterile plates (Greiner). The seeded plates are incubated overnight at 37°C in 5% COg. Human orexin-A as an agonist is prepared as 1 mM stock solution in MeOH: water (1:1), diluted in HBSS containing 0.1 % bovine serum albuiiun (BSAj, NaHCUj; 0.375g/l and 20 mM HEPES for use in the assay at a final concentraLiuii ol 3 iiM. Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 384-well plates, first in DMSO, then in HBSS containing 0.1 % bovine serum nibumin (BSA), NaHCOg: 0.375g/l and 20 mM HEPES. On the day of the assay, 50 ii\ of staining buffer (HBSS containing 1% FCS, 20 mM HEPES, NaHCOs: 0.375g/l, 5 mM probenecid (Sigma) and 3 ]xM of the fluorescent calcium indicator fluo-4 AM (1 mM stock solution in DMSO, containing 10% pluronic) is added to each well. The 384-well cell-plates are incubated for 50 min at 37" C in 6% CO2 followed by equilibration at RT for 30-120 min before measurement. Within the Fluorescent Imaging Plate Reader (FLIPR2 or FLIPR Tetra, Molecular Devices), antagonists are added to the plate in a volume of 10 fil/well, incubated for 10 min and finally 10 )il/well of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the fluorescence peak induced by 3 nM orexin-A with vehicle in place of antagonist. For each antagonist, the IC50 value (the concentration of compound needed to inhibit 50 % of the agonistic response) is determined. Optimized conditicns may be achieved by adjustment of pipetting speed and cell splitting regime. The calculated IC50 values of the compounds may fluctuate depending on the daily cellular assay performance. Fluctuations of this kind are known to those skilled in the art. Antagonistic activities (IC50 values) of all exemplified compounds are below 1000 nM with respect to the 0X1 and/or the 0X2 receptor. IC50 values of 267 exemplified compounds are in the range of 1.9-8626 nM with respect to the 0X1 receptor; 10 compounds have been measured with an IC50 value >10000 nM in this assay. IC , values of 277 exemplified compounds are in the range of 0.6-147'. iiM with respect to the 0X2 receptor; 2 compounds have been measured with an IC50 value >10000 nM in this assay. Antagonistic activities of selected compounds are displayed ut Table 1 Table 1 We Claim 1. A compound of formula (I) wherein R1 represents hydrogen, (C1-6)alkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl-(C1-4)alkyl, or aryl-(C1-4)alkyl, wherein the aryl is unsubstituted, or mono-substituted, wherein tho substituent is selected from the group consisting of (C1-4)alkyl, (Ci-4)alkoxy, trifluoromethyl, and halogen; R2 represents hydrogen, (c3-4)alkyl, (C3-6)cycloalkyl, or aryl-(C1-4)alkyl, wherein the aryl is unsubstituted, or mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, trifluoromethyl, and halogen; wherein R1 and R2 do not represent hydrogen at the same time; R3 represents heterocyclyl, which is unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, and trifluoromethyl; R4 represents (C1-4)alkyl, bromo, cyclopropyi, or-NR5R6; R5 represents hydrogen, or (C1-4)alkyl; R6 represents hydrogen, or (C1-4)alkyl; and D represents aryl, which is unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C1-4) alkyl, (C1-4) aikoxy, trifluoromethyl, trifluoromethoxy, cyano, and halogen; or a salt of such a compound. 2. A compound of formula (I) according to claim 1, wherein A i epresents or a salt of such a compound. 3. A compound of formula (I) according to claim 1 or 2, wherein R1 repiusenid methyl, -NHg, bromo, or cyclopropyl; or a salt of such a compound. 4. A compound of formula (I) according to any one of claims 1 to 3, wherein D represents phenyl, which is unsubstituted, mono- or di-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, trifluoromethyl, cyano, and halogen; or a salt of such a compound. 5. A compound according to any one of claims 1 to 4, wherein R1 represents hydrogen, methyl, cyclopropyl, cyclopropyl-methyl, oraryl-(C1-4)alkyl wherein the aryl is unsubstituted, or mono-substituted, wherein the substituent is selected from the group consisting of trifluoromethyl, and halogen; or a salt of such a compound. 6. A compound according to any one of claims 1 to 5, wherein R2 represents hydrogen, methyl, cyclopropyl, or aryl-(C1-2)alkyl, wherein the aryl is unsubstituted; or a salt of such a compound. 7. A compound according to any one of claimb 1 to 6, wherein R3 represents a group selected from quinoline-8-yl, isoquinoline-1-yl, indol-3 yl, indol-4-yl, indol-7-yl, indazol-3-yl, inda2ol-4-yl, indazol-T-yi, benzofuran-4-yl, benzofuran-7-yl, benzisoxazol-3-yl, benzisoxazol-4-yl, ben2isoxazol-7-yl, benzoxazol-4-yl, benzoxazol-7-yl, benzoxadiazol-4-yl, benzoxadiazol-7-yl, benzothiophene-3-yl, benzothiophene-4-yl, benzothlophene-7-yl, benzthiazoi-4-yl, benzthiazol-7-yl, benzoisothiazol-3-yl, benzoisothiazol-4-yl, benzoisothlazol-7-yl, benzothiadiazol-4 yl, benzothiadiazol-7-yl, benzimidazol-4-yl, benzimidazol-7 yl, imidazo[2.1-b]thiazol-3-yl, imidazo[2,1-b]thiazol-5-yl, pyrazolo[1,5-a]pyridine-3-yl, imidazo[1,2-a]pyridine-3-yl, 2,3-dihydro-thieno[3,4-b][1,4]dioxine-5-yl, benzo[1,3]dioxol-4-yl, 2,3-dihydro- benzofuran-4-yt, 2,3-dihydro-benzofuran-7-yl, 4H-benzo[1,3]dioxin-8-yl, 4H- benzo[1,3]dioxin-5-yl, and 2,3-dihydro-benzo[1,4]dioxin-5-yl; wherein said group is unsubstituted, mono-, or di-substituted, wherein the substituents are independently selected from the group consisting of methyl, methoxy, halogen, and trifluoromethyl; or a salt of such a compound. 8. A compound according to any one of claims 1 to 6, wherein R3 represents Or salt such acompound. 9. A compound according to any one of claims 1 to 8 selected from the group consisting of; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-1 -cyclopropyl-ethyl}-methyl-amide; 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-benzyl-amide; 5-(4-Fiuoro-phenyl)-2-methyi-thiazole-4-carboxyiicacid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-methyl-amide; 1-Methyl-1H-indazole-3-carboxylic acid (2-{[5-(4-fluoro-phenyl)-2-melhyi-Ltiiazole-H carbonyl]-methyl-amino}-ethyl)-amide; 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylicacid {2-[(2,3-d)hydro-benzoturan-7-carbonyl)-amino]-ethyl}-methyl-amide; 6-Methyl-imidazo[2,1-b]thiazo(e-5-carboxylic acid {2-{\ i fluoro-pfleyl)-2-methyl-thiazole-4-carbonyl]-methyl-amino}-ethyl)-amide; 5-(4-Fliioro-phenyl)-2-methyl-thiazote-4-carboxylicacid benzyl-{2-f(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 1-Methyl-1/-/-indazole-3-carboxylic acid (2-{benzyl-[5-('-fluoro piie(iyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide; 5-{4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid benzyl-{2-[(2,3-dihydro-benzofuran-7-carbonyl)-amino]-ethyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-{benzyl•[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-ethyl}-(3,3-dimethyl-butyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylicacid{2-[(3,3-dimethyl-butyl)-(2-methyl-5-phenyl-thiazole-4-carbonyl)-amino]-ethyl}-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-(3,3-dimethyl-butyl)-amlde; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino] ethyl}-(3-phenyl-propyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[(2-methv> J plienyl-lhiazolo 4- carbonyl)-(3-phenyl-propyl)-amino]-ethyl}-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(2,3-dihydro-benzon 4]dioxino -5- carbonyl)-amino]-ethyl}-(3-phenyl-propyl)-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]- ethyl}-(4-fluoro-benzyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[(4-fluoro-benzyl)-(2-methyl-5- phenyl-thiazole-4-carbonyl)-amino]-ethyl}-amide; 2-Methyl-5-phenyl-thia2ole-4-carboxylic acid {2-[(2,3-dJhydro-benzo[1,4]dioxine-5- carbonyl)-annino]-ethyl}-(4-fiuoro-benzyl)-annide; 2-IVlethyl-5-pinenyl-thiazole-4-carboxyiic acid {2-[(benzofuran-4-carbonyl)-amino]- ethyl}-phenethyl-amide; 6-Methyl-imidazo[2,1-b]thiazoie-5-carboxylic acid{2-[(2-methyl-5-phenyl-thiazole-4- carbonyl)-phenethyl-amino]-ethyl}-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(2,3-dihydro-ben2o[1,4]dioxine-5- carbonyl)-amino]-ethyl}-phenethyl-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzoturan-4-carbonyl)-ariiino]- ethyl}-(4-trifluoromethyl-benzyl)-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-[(2-methyl-5-phenyl-thiazole-4- carbonyl)-(4-trifluoromethyl-benzyl)-amino]-ethyl}-amide; 2-IVlethyl-5-phenyi-thiazole-4-carboxylic acid {2-[(2,3-dihydro-benzo[1,4]dioxine-5 carbonyl)-amino]-ethyl}-(4-tr(fluoromethyl-benzyl)-amide; 2-l\/lethyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyi)-aiiii(io]- ethyi}-cyclohexylmethyl-amide; 6-Methyl-imida2o[2,1 -b]thiazole-5-carboxylic acid {2-[cyclohexylmethyl-(2-methyl-5- phenyl-thiazole-4-carbonyl)-amino]-ethyl}-amide; 2-l\/lethyl-5-phenyl-thiazote-4-carboxylic acid cyclohexylnnelliyl-{2 [(2,3-dihydro- benzo[1,4]dioxJne-5-carbonyl)-amino]-ethyl}-amide; 2-l\/Iethyl-5-phenyi-thiazole-4-carboxylic acid {2-[(benzofuran 4-carbonyl)-arnii lo]- ethyl}-isobutyl-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-[isobutyl-(2-methyl-5-phenyl- thiazoie-4-carbonyl)-annino]-ethyl}-annide; 2-l\/!ethyl-5-phenyl-thiazole-4-carboxylic acid {2-[(2,n dihydro-benzo[1,4]diuxine-5- carbonyl)-amino]-ethyl}-isobutyl-amide; 2-Methyl-5-pheny!-thiazole-4-carboxylic acid {2-[(benzofLiran-4-carbonyl)-amino]- ethyl}-cyclopropylmethyl-amicle; 6-Methyt-imidazo[2,1-b]thiazole-5-carboxyiic acid {2-[cyc!opropylmethyl-(2-methyl-5- phenyl-thiazole-4-carbonyl)-amino]-ethyl}-amide; 2-l\/!ethyl-5-plienyl-thiazole-4-carboxylic acid cyclopropyiniethyi-{z-[(2,3 diiiycito- benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-l\/lethyl-5-ptienyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]- ethyl}-ben2yl-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-[benzyl-(2-methyl-5-phenyl- thia2oie-4-carbonyl)-amino]-ethyl}-amide; 2-Methyl-5-phenyl-tiiiazole-4-carboxylic acid benzyl-{2-[(2,3-dihydro- ben2o[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylJc acid {2-[(benzofuran-4-carbonyl)-aminoJ- ethyl}-nnethyi-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[metliyl-(2-methyi-b-phenyl- thiazole-4-carbonyl)-amino]-ethyl}-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(2,3-dihydro-berizo[1,4]dioxine-5- carbonyi)-amino]-etlnyl}-metliyl-annide; 2-Methyi-5-phenyl-thiazole-4-carboxylic acid {2-[(benzo1uran-4 carbonyl)-aiiiii loj- ethyl}-cyclopropyl-amide; 6-i\/lethyl-imidazo[2,1-b]thiazole-5-carboxyiic acid {2-[cyciopropyl-(2-methyl-5-phenyi- ttiiazole-4-carbonyl)-amino]-etliyl}-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro- benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Methyl-5-phenyl-tliiazole-4-carboxylic acid {2-[(benzofuran-4-c;irbonyI) amino]-1- cyclopropyl-ethyl}-benzyl-amide; 2-l\/lethyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-atnino]-1 - cyclopropyi-ethyl}-amide; Benzofuran-4-carboxylic acid {2-[(biphenyl-2-carbonyl)-amino]-2-cjyclopropyl-ethyij- amide; 6-IVlethyl-imida2o[2,1 -b]thiazole-5-carboxylic acid {2-cyclopropyl-2-[methyl-(2-methyl- 5-phenyl-thiazoie-4-carbonyl)-amino]-ethyl}-amide; 6-l\/lethyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[benzyl-(2-methvl-5-p|-ienyl- tliiazole-4-carbonyl)-amino]-2-cyclopropyl-ethyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-cyclopropyl-2-[(2-methyl-5- phenyi-thiazole-4-carbonyl)-amino]-ethyl}-amide; 6-Methyl-imida2o[2,1 -b]thiazole-5-carboxyiic acid {2-[(biphenyl-2-cartjonyl)~aminoJ-2- cyclopropyl-ethyl}-amide; 2-Methyl-5-phenyl-thiazole-4-carboxyiic acid (1 -{[(benzofuran -I •carbonyl)-annino]- nnethyl}-3-phenyl-propyl)-methyl-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid (1 -{[(benzofuran-4-carbonyl)-amino]- iTiethyl}-3-phenyl-propyl)-ben2yl-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid (1-{[(benzofuian-i carboriyl)-arriinuJ- methyl}-3-phenyl-propyl)-amide; Benzofuran-4-carboxylic acid{2-[(biphenyl-2-carbonyl)-amino]-4-phenyl-butyl[amiui6-IVIetliyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[methyl-(2-in&tiiyl 5-phenyl- thiazo!e-4-carbonyl)-annino]-4-phenyl-butyl}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[benzyI-(2-ine1hyl 5-phenyl- thiazole-4-carbonyl)-amino]-4-phenyl-butyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-[(2-methyl-5-phenyl-thiazole-4- carbonyl)-amino]~4-phenyl-butyl}-amide; 6-!\/lethyl-imidazo[2,1 -b]tliiazole-5-carboxylic acid {2-[(biphenyl-2-carbonvl)-amino]-4- phenyl-butyl}-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzotura(i-4-carbonyl)-aminoJ-1 - methyl-ethyl}-methyl-amide; 2-Methyl-5-phenyl-thiazole-4-carboxyiic acid {2-[(benzofuran-4-carb(Jiiyi) arninoj 1 methyl-ethyl}-benzyl-amide; 2-l\/lethyi-5-phenyl-thiazole-4-carboxylic acid {2-[(benzo(u(ari 4 carbonyl)-amlno]-1- methyl-fithyl}-amide: Benzofuran-4-carboxylic acid {2-[(biphenyl-2-carbonyiy .;inino]-propyl} amide; 6-l\/lethyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-[benzyl (2-methyl-5-pheny!- thiazole-4-carbonyl)-amino]-propyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-[(2-methyl-5-phenyl-thiazole-4- carbonyl)-amino]-propyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-[(biphenyl-2-carbonyi)-amino]- propyl}-amide;. . 2-l\/Ietfiyl-5-phenyl-tliiazole-4-carboxylic acid{2-[(benzofuran-4-carbonyl)-amino]-1- benzyl-ethyl}-methyl-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-1 - benzyl-ethy!}-benzyl-amide; 2-l\yiethyl-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]-1- benzyl-ethyl}-amide; Ben2ofuran-4-carboxylic acid {2-[(biphenyl-2-carbonyl)aii,iiio] 3 (:-lit: iyl propyl}- amide; 6-IV1ethyl-fmidazo[2,1-b]thiazole-5-carboxylic acid {2-[methyi--(2methyl '■; phenyl- thiazole-4-carbonyl)-amino]-3-phenyl-propyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-[benzyl-(2-methyl-5-phenyl- thiazole-4-carbonyl)-amino]-3-phenyl-propyl}-amide; 6-Methyi-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[{2-methyl-5-phenyl-thiazole-4- carbonyl)-amino]-3-phenyl-propyl}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[(biphenyl-2-carbonyl)-amino]-3- phenyl-propyl}-amide; 2-IVIethyl-5-phenyl-thiazoie-4-carboxylic acid (1 -{[(benzofuran-4-carbonyl)-amino]- methyl}-2-methyl-propyl)-metliyl-amide; 2-l\/lethyl-5-phenyl-thiazole-4-carboxylic acid (1-{[(benzoiuran-4 i,aiboii>;; oniino]- methyi}-2-methyi-propyl)-benzyl-amide; 2-Methyl-5-phenyi-thiazole-4-carboxyiic acid (1-{[(benzofuran-4-carbonyl)-amino]- methyl}-2-methyl-propyl)-amide; Benzofuran-4-carboxylic acid {2-[(biphenyl-2-carbonyl)-aminoJ-3-methyl-bulyl} amide; 6-Methyl-imidazo[2,1-b]thiazoie-5-carboxylic acid {2-[benzyl {2-methyl-5-phenyi- thiazole-4-carbonyl)-amino]-3-methyi-butyl}-amide; 6-l\/lethyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {3-methyl-2-[(2-methyl-5 -phenyl- thiazole-4-carbonyl)-amino]-butyl}-amide; 6-l\/lethyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[(biphenyl-2-carbonyl)-ainino]-3- methyl-buty!}-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylicacid (1-{[(benzofuran-4-carbonyl) ainino]- methyl}-3-methyl-butyl)-methyl-amide; 2-Methyl-5-phenyl-thiazo(e-4-carboxylic acid (1-{[(benzofuraii 4-carbonyl)amino]- methyl}-3-methyl-butyl)-benzyl-amide; 2-Methyl-5-phenyl-thiazole-4-carboxylic acid (1-{[(benzofuran-4-carbonyl) amino]- methyl}-3-methyl-butyl)-amide; Benzofuran-4-carboxylic acid {2-[(biphenyl-2-carbonyl)-amino]-4-methyl-pentyl}- amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {4-methyl-2-[methyl-(2-methyl-5- phenyl-thiazole-4-carbonyl)-amino]-pentyl}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[benzyl-(2-methyl-5-phenyl- thiazoie-4-carbonyl)-amino]-4-methyl-pentyl}-amide; 6-l\/lethyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {4-methyl-2-[(2-methyl-5-phenyl- thiazoie-4-carbonyl)-amino]-pentyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-[(biphenyl 2-carbonyl)-amino]-4- methyl-pentyl}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[(biphenyl-2-carbonyl)-methyl- amino]-2-cyclopropyl-ethyl}-amide; 6-l\/lethyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[(biplienyl-2-carbonyl)-metiiyl- amino]-4-phenyl-butyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-f(biphenyl-2-carl)onyl)-methyl- amino]-propyl}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[(biphenyl-2-carbonyi)-methyl- amino]-3-phenyl-propyl}-amide; 6-Methyl-imidazo[2,1-b]tliiazole-5-carboxylic acid {2-[(biphenyl-2-carhonyl)-methyl amino]-3-methyl-butyl}-amide; 6-i\/Iethyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-[(biphenyi-2-carbonyl)-methyl- amino]-4-methyl-pentyl}-amide; 6-IVIethyl-imidazo[2,1-b]tliiazole-5-carboxylic acid {2-[bL, . :- |)honyl-2-cari, -nyl)- amino]-2-cyclopropyl-ethyi}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[benzyl-(biphenyl-2 drbonyl)- annino]-4-phenyl-butyl}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylicacid {2-[benzyl-(biphenyl-2-carbonyi) amino]-propyl}-amide; 6-l\/lethyl-imidazo[2,1-b]thiazole-5-carboxyiicacid{2-[benzyl-(biphenyl-2-carbonyl)- amino]-3-phenyl-propyl}-amide; 6-Methyl-imidazo[2,1-blthiazole-5-carboxylic acid {2-[ben/>, ',ui|ji.unyl-2carbonyl) amino]-3-methyl-butyl}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[benzyl-(biphenyl-2-carbonyl) amino]-4-methyl-pentyt}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid{2-[cyclopropyl-(2-cyclopropyl-5 phenyl-thiazole-4-carbonyl)-amino]-ethy(}-amide; 6-l\/1ethyl-imida2o[2,1-b]thiazole-5-carboxylic acid {2-[cyclopropyl-(2-cyciopropyl-5-m- tolyl-thiazole-4-carbonyl)-amino]-ethy!}-amide; 6-Methyi-imidazo[2,1-b]thiazole-5-carboxylicacid (2-{cyclopropyl-[2-cyclopropyl-5-(3- methoxy-phenyl)-thiazole-4-carbonyl]-amino}-ethyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylicacid {2-[(2-amino-5-m-tolyl-thiazole-4- carbonyl)-cyclopropyl-amino]-ethyl}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylicacid (2-{[2-amino-5-(3-tluoro-phenyl)- thiazole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[2-amino-5-(3-metliOAy phenyl)-thiazole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amide, 6-Methyl-imidazo[2,1-b]thiazoie-5-carboxylic acid (2-{[2-amino-5-(4 fliioro-phenyl)-thiazole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[2-amino-5-(3-cliIoro-phenyl)-thiazole-4-carbonyl]-cyciopropyl-amino}-etinyl)-amide; 6-Methyl-innidazo[2,1 -b]thiazole-5-carboxylic acid {2-[(2-amino-5-phenyl-thiazole-4-carbonyl)-cyclopropyl-amino]-ethyi}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[2-bromo-5-(3-methoxy-phenyl)-tliiazoie-4-carbonyi]-cyclopropyl-amino}-etliyl)-amide; 6-Methyl-imida2o[2,1 -b]thiazole-5-carboxylic acid {2-[(2-bromo-5-p-tolyl-thiazole-4-carbonyl)-cyclopropyl-amino]-ethyl}-amide; 6-l\/lethyl-imida2oI2,1-b]thiazole-5-carboxylic acid (2-{cyclopropyl-[5-(2-fluoro-phenyl)-2-metliyl-tliiazole-4-carbonyl]-amino}-ethyl)-amide; 6-IVlethyl-innidazo[2,1-b]thiazole-5-carboxylicacid (2-{cyclopropyl-[2-metlnyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-ethyi; uimuo, 6-Methyl-imidazo[2,1-b]thia20le-5-carboxylicacid (2-{( yclopropyl-[5-(3-fluoro-phenyl)-2-methyl-thtazole-4-carbonyl]-amino}-etliyl)-amide; 6-l\/lethyl-innidazo[2,1-b]thiazole-5-carboxylic acid (2-{cyclopropyl-[2-methyl-5-(4-trifiuoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-ethyl)-aiTiide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[5-{4-ctiloro-phenyl)-2-methyl thiazole-4-carbonyi]-cyclopropyl-amino}-ethyl)-amide; 6-Methyl-imida7n[2.1-b]thiazole-5-carboxylic acid (2-{cyclopropyl-[5-(3-methoxy-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[5 (3-cyano-phenyI)-2-methyl-thiazole-4-carbonyl]-cyclopropyl-amino}-ethyl)-amide; 6-IVletliyl-innidazo[2,1-b]thiazole-5-carboxylicacid (2-{cyclopropyl-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyi)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[cyclopropyi-(2-methyt b-p-to)yl-thiazole-4-carbonyl)-amino]-ethyl}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[cyclopropyr (3 -metlyl-biphenyl-2-carbonyl)-amino]-ethyi}-amide; 6-IVlethyl-imidazo[2,1-b]thiazoie-5-carboxylic acid {2-[cyc(opropyi-(4-riieihyi-biphenyl-2-carbonyl)-amino]-ethyl}-amide; 6-Methyi-imidazo[2,1-b]thiazole-5-carboxylicacid {2-[cyclopropyl-(4'-fluoro-biphenyl-2-carbonyl)-amino]-ethyl}-amide; 1 -Methyl-1 H-indazole-S-carboxylic acid {2-[cyclopropyl-(2-cyclopropyl-5-pheMyl- thiazole-4-carbonyl)-amino]-ethyl}-annide; 1 -Methyl-1 H-indazole-3-carboxylic acid {2-[cyclopropyl-(2-cyclopropyl-5-/r;-Lolyl- thiazole-4-carbonyl)-amino]-ethyl}-amide; 1-Methyi-1H-indazole-3-carboxylic acid (2-{cyclopropyl-[2-cyclopropyl-5-(3-methoxy phenyl)-thiazole-4-carbonyl]-amino}-ethyl)-amide; 1 -Methyl-1H-indazole-3-carboxylic acid {2-[(2-amino-5-/77-tolyl-thia2ole-4-carbonyl)- cyclopropyl-amino]-ethyl}-amide; 1-Methyl-1H-indazole-3-carboxylic acid (2-{[2-amino-5-(3-fluoro-phenyl)-thia2ole-4- carbonyl]-cyclopropyl-amino}-ethyl)-amide; 1-Methyl-1 H-indazole-3-carboxylic acid (2-{[2-amino-5-(3-methoxy-phenyl)-thiazole- 4-carbonyl]-cyclopropyl-amino}-ethyl)-amide; 1-Methyl-1 H-indazole-3-carboxylic acid (2-{[2-amino-5-(4-fluoro-phenyl)4hiazole-4 carbonyl]-cyclopropyl-annino}-ethyl)-amide; 1-Methyl-1/-/-indazole-3-carboxylic acid (2-{[2-amino-5-(3-chioio-pheny!) -thiazole-4 carbonyl]-cyclopropyl-amino}-ethyl)-amide; 1-Methyl-1 H-indazole-3-carboxylic acid {2-[(2-amino-5-phenyl~thiazuic--H-Gaibunyl)- cyclopropyl-amino]-ethyl}-amide; 1 -Methyi-1 /-/-indazole-3-carboxylic acid (2-{[2-bromo-5-(3-methoxy-phenyl)-thiazole- 4-carbonyl]-cyclopropyl-amino}-ethyl)-amide; 1 -Methyl-1H-indazole-3-carboxylic acid {2-[(2-bromo-5-p-tolyl-thiazole-4-carbonyl)- cyclopropyl-amino]-ethyl}-amide; 1-Methyl-1/-/-indazole-3-carbnxylic acid (2-{cyclopropvl-[5-(2-fluoro ptienvl)-2 niethyl- thiazole-4-carbonyl]-amino}-ethyl)-amide; 1-Methyl-1 H-indazole-3-carboxylic acid (2-{cyclopropyl-[2-methyl-5-(3-trifluoronnethv1- phenyl)-thia2ole-4-carbonyl]-annino}-ethyl)-amide; 1-Methyl-1/-/-indazole-3-carboxylic acid (2-{cyclopropyl-[5-(3-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-amino}-ethyl)-amide; 1-Methyl-1 H-indazole-3-carboxylic acid (2-{cyclopropyl-[2-methyl-5-(4-trifluoromethyl- phenyl)-thiazole-4-carbonyl]-amino}-ethyl)-amide; 1-Methyl-1 H-indazole-3-carboxylic acid (2-{[5-(4-chloro-phenyl)-2-fiiolliyl-thiazole-4- carbonyl]-cyclopropyl-amino}-ethyl)-amide; 1 -Methyl-1/-/-indazole-3-carboxylic acid (2-{cyclopropyl-[5-(3-methoxy-phenyl)-2- methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide; 1-Methyl-1 H-indazole-3-carboxylic acid (2-{[5-(3-cyano-phenyl)-2-meltiyl-lhiazole 4 carbonyl]-cyclopropyl-amino}-ethyl)-amide; 1-Methyl-1/-/-inciazole-3-carboxylicacid (2-{cyclopropyl-[5-(3,4-ciinnethyl-phenyl)-2- methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide; 1-Methyl-1/-/-indazole-3-carboxylic acid {2-[cyclopropyl-(2-methyl-5-p-tolyt-thiazole-4- carbonyl)-annino]-ethyl}-amide; 1-Methyl-1/-/-inda2ole-3-carboxylic acid {2-[cyclopropyl-(3'-metliyl-biprienyl-2- carbonyl)-amino]-ethyl}-amide; 1 -Methyl-1 /-/-indazole-3-carboxylic acid {2-[cyclopropyl-(4'-methyl-bip|-ienyl-2- carbonyl)-amino]-ethyl}-amide; 1-Metliyi-1H-indazole-3-carboxylic acid{2-[cyclopropyl(4'-fiuoro-biphenyl-2- carbonyl)-amino]-ethyl}-amide; 2-Cyclopropyl-5-phenyl-thia2o)e-4-carboxylic acid {2-[(benzofuran-4-carbonyl)- amino]-ethyl}-cyclopropyl-amide; 2-Cyclopropyi-5-m-tolyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)- amino]-ethyl}-cyclopropyl-amide; 2-Cyciopropyl-5-(3-methoxy-phenyl)-thiazole-4-carboxyiic acid {2-[(benzofuran-4- carbonyl)-amino]-etliyl}-cyclopropyl-amide; 2-Amino-5-m-tolyl-thiazole-4-carboxylic acid {2-[(benzofuran 4 L,arboivyi)-anninoJ- ethyl}-cyclopropy!-amide; 2-Annino-5-(3-fluoro-phenyi)-thiazole-4-carboxylic acid{2-[(benzofuran-4-carbonyl)- amino]-etlnyl}-cyclopropyl-amide; 2-Amino-5-(3-methoxy-phenyl)-thiazole-4-carboxylicacid{2-[(benzofuran-4- carbonyl)-amino]-ethyl}-cyclopropyl-amide; 2-Amino-5-(4-fluoro-piienyl)-thiazole-4-carboxylic acid {2-[{benzofuran-4-carbonyl)- amino]-ethyl}-cyclopropyl-amide; 2-Amino-5-(3-chloro-phenyi)-thiazole-4-carboxylic acid{2-[(benzofuran-4-carbony()- amino]-etliyl}-cyclopropyl-annide; 2-Amino-5-phenyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]- ethyl}-cyclopropyl-amide; 2-Bromo-5-(3-methoxy-plienyl)-thiazole-4-carboxylic acid {2-[(ben2o(uian 4- carbonyl)-amino]-ethyl}-cyclopropyl-amide; 2-Bromo-5-p-tolyl-thia2oie-4-carboxylic acid{2-[(benzofuran-4-carbonyi)-amino]- etliyl}-cyciopropyl-amide; 5-(2-Fluoro-phenyl)-2-metliyl-tliiazole-4-carboxylicacid{2-[(ben2ofuran-4-carbonyl)- amino]-ethyl}-cyclopropyl-amide; 2-IVIetliyt-5-(3-trifluorometliyl-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4- carbonyl)-annino]-ethyl}-cyclopropyl-amide; 5-(3-Fluoro-phenyl)-2-nnethyl-thiazole-4-carboxylic aciu {2-[(benzofuran-4-carbonyl)- amino]-ethyl}-cyclopropyl-amide; 2-Methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylicacid{2-[(benzofuran-4- carbonyl)-amino]-ethyl}-cyclopropyl-amide; 5-(4-Chloro-phenyl)-2-methyl-thiazole-4-carboxylicacid {2-[(benzofuran-4-carbony!)- amino]-ethyl}-cyclopropyl-amide; 5-(3-Methoxy-phenyl)-2-methyl-thiazole-4-carboxylic acid {2 f(benzofuran-4- carbonyl)-amino]-ethyl}-cyclopropyl-amide; 5-(3-Cyano-phenyl)-2-methyl-thiazole-4-carboxylic acid{2-[(benzofuran-4-carbonyl)- amino]-ethyl}-cyclopropyl-amide; 5-(3,4-Dimethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid {2 [(l)enzofiiran-4- carbonyl)-amino]-ethyl}-cyclopropyl-amide; 2-Methyl-5-p-tolyl-thiazole-4-carboxylicacid {2-[(benzofuran-4carbonyl)-amino]- ethyl}-cyclopropyl-amide; Benzofuran-4-carboxylic acid {2-[cyclopropyi-(3'-methyl-biphenyl- uai uonyl)-amino]- ethyl}-amide; Benzofuran-4-carboxylic acid{2-[cyclopropyl-(4'-nnethyi-biphenyl-2-carbonyi)-amino]- ethyl}-amide; Benzofuran-4-carboxyiic acid {2-[cyctopropyl-(4'-fluoro-biphenyl-2-ccii bonyi)-amino]- ethyl}-amide; 6-l\/!ethyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[cyclopropyimethyl-(2- cyclopropyl-5-phenyl-ttiiazole-4-carbonyl)-amlno]-ethyl}-amide; 6-Methvl-imidazo[2,1-b]thiazole-5-carboxylic acid {2 [cyciopropylmethyl(2- cyclopropyl-5-/T?-tolyl-thiazole-4-carbonyl)-amino]-etliyl}-amidei 6-i\/Iethyl-imidazo[2,1-b]thiazole-5-carboxylicacid (2-{[2-cyclnpropyl-5-(3-methoxy phenyl)-tlniazole-4-carbonyl]-cyclopropylmetliyl-amino}-ethyl) amide- 6-Methyl-imidazo[2,1 -b]tliiazoie-5-carboxylic acid {2-[(2-amino-5-m-tolyl-thiazole-4- carbonyl)-cyclopropylmethyl-amino]-ethyl}-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylicacld (2-{[2-amino-5-(3 tluoro-phenyl)- thiazole-4-carbonyl]-cyclopropylmethy!-amino}-ethyl)-amide; 6-IVIethyl-imidazo[2,1-b]tliiazole-5-carboxylic acid (2-{[2-amino 5(3 methoxy-phenyl)- tliiazole-4-carbonyl]-cyclopropylmetliyl-amino}-ethyl)-amide, 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylicacid (2 {[2 amino-5-(4-fluoro-phenyl) thiazole-4-carbonyl]-cyclopropylmethyl-amino}-etlnyl)-amicie, 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid (2-{[2-amino-5-(3-chloro-phenyl)- thiazole-4-carbonyl]-cyclopropylmethyl-amino}-ethyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid {2-[(2-amino-5-phenyl-thiazole-4- carbonyl)-cyclopropylmethyl-amino]-ethyl}-amide; 6-Methyl-(midazo[2,1 -b]thiazole-5-carboxylic acid (2-{[2-bromo-5~(3-n lerhoxy-phenyl) thiazole-4-carbonyl]-cyclopropyimettiyl-amino}-ethyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxyiic acid {2-[(2-bromo '") p-tolyl-thiazole-4- carbonyl)-cyclopropylnnettiyl-amino]-ethyl}-amide; 6-l\/lethyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{cyclopropylmetl-iyl-[5-(2-(luoro- phenyi)-2-methyl-thiazoie-4-carbonyl]-amino}-ethyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{cyclopropylmethyl-[2-methyl-5- (3-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-ethyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{cyclopropylmethyl[5-(3 (luoro- phenyl)-2-nnethyl-tliiazole-4-carbonyl]-amino}-ethyl)-arnide; 6-Methyi-innidazo[2,1-b]thiazole-5-carboxylic acid (2-{cyclopropyliri«jl.liyl [2 n filiyl 5 (4-tnfluoromethyl-phenyl)-thia2ole-4-carbonyl]-amino}-ethyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{[5-(4 chloro-phenyl)-2-iTiethyl- thia2ole-4-carbonyl]-cyclopropyimethyi-amino}-ethyl)-amide; 6-l\/lethyl-imidazo[2,1-b]thiazole-5-carboxyiic acid (2-{cyciopropyimetliyl-15 (3- methoxy-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid (2-{[5-(3-cyano-phenyl)-2-nnethyl- thia2ole-4-carbonyl]-cyclopropylmethyl-annino}-ethyl)-amide; 6-Methyl-imidazo[2,1-b]thiazole-5-carboxylic acid (2-{cyclopropylrm;ihyl-[5 (3,4- dimethyl-phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide; 6-IVIethyi-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-[cyclopropylmetliyl-(2-methyl-5- p-tolyl-thiazole-4-carbonyi)-amino]-ethyl}-amide; 6-iVlethyl-innidazo[2,1-b]thiazoie-5-carboxylic acid {2-[cyclopiopylnieiiiyi io -methyl biphenyl-2-carbonyl)-annino]-ethyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {2-[cyclopropylmethyl-(4'-methyl- biphenyl-2-carbonyl)-amino]-etiiyl}-amide; 1-Methyl-1H-indazole-3-carboxylic acid {2-[cyclopropylmethyl-(2-cyclopropyl-5- phenyl-thiazole-4-carbonyl)-aminc]-ethyl}-amide; 1 -Methyl-1 /-/-indazole-3-carboxylic acid {2-[cyclopropylmethyl-(2-cyclopropyl-5-m- tolyl-thiazole-4-carbonyl)-annino]-ethyl}-annide; 1 -IVIethyl-l H-indazole-3-carboxylic acid (2-{[2-cyclopropyl-5-(3-methoxy-phenyl)- thiazole-4-carbonyl]-cyc!opropylmethyl-amino}-ethyl)-amide, 1-IVlethyl-1/-/-indazole-3-carboxylic acid {2-[(2-amino-5-m-tolyl-thiazole-4-carbonyl)- cyciopropylmethyl-amino]-ethyl}-amide; 1-Methyl-1H-indazole-3-carboxylic acid (2-{[2-amino-5-(3-fluorophenyl)-thiazole-4- carbonyl]-cyclopropylmethyl-annino}-ethyl)-amide; 1-Methyl-1/-/-inda2ole-3-carboxy!ic acid (2-{[2-amirio-5-(3-meiiioxy-phenyl)-thiazole- 4-carbonyl]-cyclopropylmethyl-amino}-ethyl)-amide; 1-Methyl-1H-indazole-3-carboxylicacid (2-{[2-amino-5-(4-fluoro-phenyl)-thiazo)e-4- carbonyl]-cyclopropy!methyl-amino}-ethyl)-amide; 1-Methyl-1H-indazole-3-carboxylicacid (2-{[2-amino-5-(3-chloro-phenyl)-triiazole-4- carbonyl]-cyclopropylmethyl-amino}-ethyi)-amide; 1 -Methyl-1 H-indazole-3-carboxyiic acid {2-[(2-amino-5-phenyl-thiazole 4-carbonyl)- cyclopropylmethyl-amino]-ethyl}-amide; 1-Methyl-1/-/-indazole-3-carboxylicacid (2-{[2-bromo-5-(3-methoxy-phenyl) thiazole- 4-carbonyl]-cyclopropylmethyl-amino}-ethyl)-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid {2-[(2-bromo-5-p-tolyl-thiazole-4-carbonyl)- cyclopropylmetliyl-amino]-ethyi}-amide; 1-i\/1ethyl-1H-indazole-3-carboxylic acid (2-{cyclopropylmethyl-[5 (2-fluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-amino}-ethyi)-amide; 1-Methyl-1/-/-indazole-3-carboxylic acid (2-{cyciopropylmethyl-[2-methyl-5 (3- trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-ethyi)-amide; 1-Methyl-1 H-indazoie-3-carboxylic acid (2-{cyclopropylmethyl-[5-(3-fluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-amino}-ethyl)-amide; 1-Methyl-1/-/-indazole-3-carboxylic acid (2-{cyclopropylmethyl-[2-nnethyl-5-(4- trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-ethyl)-amide; 1-Methyl-1 H-indazole-3-carboxylic acid (2-{[5-(4-chloro-phenyl)-2-mGthyl-thiazole-4- carbonyl]-cyclopropylmethyl-amino}-ethyl)-amide; 1-Methyl-1 H-indazole-3-carboxylic acid (2-{cyclopropylmethyl-[5-(3-methoxy-phenyl)- 2-methy(-thiazole-4-carbonyl]-amino}-ethyl)-amide; 1-Methyl-1/7-indazole-3-carboxylic acid (2-{[5-(3-cyano-phenyl)-2-(riythyl lhiazole-4- carbonyl]-cyclopropylmethyl-amino}-ethyl)-amide; 1 -Methyl-1H-indazole-3-carboxylic acid {2-{cyclopropylmethyl-[5-(3,4-dimetiiyl- phenyl)-2-methyl-thiazole-4-carbonyl]-amino}-ethyl)-ainide; 1-Methyl-1 H-indazole-3-carboxylic acid {2-[cyclopropylmethyl-(2 methyl-5-p-tolyl- thiazole-4-carbonyl)-amino]-ethyl}-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid {2-[cyclopropylmethyl-(3'-methyl-bJphenyl-2- carbonyl)-amino]-ethyl}-amide; 1 -Methyl-1H-indazole-3-carboxylic acid {2-[cyclopropyimethyl-(4'-mulhyl-biplienyl-2- carbonyl)-amino]-ethyl}-amide; 1-Methyl-1H-inciazole-3-carboxylic acid {2-[cyclopropylniothyl-(4'-fluof( bi))lienyl-2 carbonyl)-annino]-ethyl}-amide; 2-Cyclopropyl-5-phenyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Cyclopropyl-5-m-tolyl-th(azole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyi}-amide; 2-Cyclopropyl-5-(3--methoxy-phenyi)-thiazole-4-carboxy(ic acid cyc(opropyl-{2-[(2,3-diliydro-benzo[1,4]dioxine-5-carbonyi)-amino]-ethyl}-amide; 2-Amino-5-m-tolyl-tliiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-ben2o[1,4]dioxine-5-carbonyl)-amino]-etliyl}-amide; 2-Amino-5-(3-fluoro-plienyl)-thiazole-4-carboxylic acid cyclopropyl42|(2,3 dihyclro benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Amino-5-(3-nnetlioxy-phenyl)-tiiiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-diiiydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide, 2-Amino-5-(4-fluoro-plnenyl)-thiazole-4-carboxylic acid cyclopropyl-{2-f(2.3-dihydro-ben2o[1,4]dioxine-5-carbonyl)-anDino]-ethyl}-amide; 2-Amino-5-(3-chloro-phenyl)-thia2ole-4-carboxylicacid cyclopropyl-{24(,3 uiiiydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyi}-amide; 2-Amino-5-phenyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Bromo-5-(3-metlioxy-plienyl)-thiazole-4-carboxylicacid cyclopropyl-{2-[(2,3-dlhydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Bromo-5-p-tolyi-tliiazole-4-carboxylic acid cyclopropyi-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-etliyl}-amide; 5-(2-Fluoro-phenyl)-2-metliyl-thiazo!e-4-carboxylic acid cyclopropyl {2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-annino]-ethyl}-amide; 2-Methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid cyciopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 5-(3-Fluoro-plienyl)-2-methyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydio benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl>-amJde; 5-(4-Chloro-phenyl)-2-methyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3 dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 5-(3-Methoxy-phenyl)-2-methyl-thiazole-4-carboxylic acid cyciopropyl-{2-[(2;3-diiiydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethy(}-amide; 5-(3,4-Dimethyl-phenyl)-2-methyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-diliydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Methyl-5-p-tolyl-thiazole-4-carboxylic acid cyclopropyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid {2-[cyclopro(.yi (3 methyl-bipi itnyl-2-carbonyl)-amino]-ethyl}-amide; 2,3-Diliydro-benzo[1,4]dioxine-5-carboxylic acid {2-[cyclopropyl-(4'-methyl-biphenyl 2-carbonyi)-amino]-ethyl}-amide; 2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid {2-[cyclopropyl-(4'-fluoro-biphenyl-2-carbonyl)-amino]-ethyl}-amide; 2-Cyclopropyl-5-phenyi-thiazole-4-carboxylicacid ryclnpropylmethyl-{2-f(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Cyclopropyl-5-/77-tolyl-thiazole-4-carboxylicacid LyCiupropylmethyi (2 [(L,J cJiliydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Cyclopropyl-5-(3-methoxy-phenyi)-thia2ole-4-carboxylic acid cyclopropylmetliyl-{2-[(2,3-dihydro-ben2o[1,4]dioxine-5-carbonyl)-aminoj-ethyl} amide; 2-Amino-5-m-tolyl-thia2ole-4-carboxylic acid cyciopropyiinoiliyi {2-Ll,ci-clltlydro-benzo[1,4]dioxine-5-carbonyl)-annino]-ethyl}-amide; 2-Amino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-diliydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Amino-5-(3-metlioxy-phenyl)-tliiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Amino-5-ptienyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Bromo-5-(3-methoxy-phenyi)-thiazoie-4-carboxylic acid cyclopropylmethyi-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Bronno-5-p-tolyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyi}-amide; 5-(2-Fluoro-phenyl)-2-methyi-thiazole-4-carboxylic acid cyclopiapylrneiliyl {2 [(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-annide, 2-l\/Iethyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid cyclopropyliiiethyl-{2-[(2,3-diliydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethvl} amide; 5-(3-Fluoro-plnenyl)-2-mettiyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-f(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyi}-amide; 5-(3-Methoxy-phenyi)-2-methyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 5-(3-Cyano-phenyl)-2-methyl-thiazole-4-carboxylic acid cyclopropy(metliyl-{2 [(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 5-(3,4-Dimethyl-phenyl)-2-methyl-thiazole-4-carboxylicacid cyclopropylmethyl-{2- [(2,3-dihydro-benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2-Methyl-5-p-tolyl-thiazole-4-carboxylic acid cyclopropylmethyl-{2-[(2,3-dihydro- benzo[1,4]dioxine-5-carbonyl)-amino]-ethyl}-amide; 2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid {2-[cyclopropylmethy!-(3'-methyl- biphenyl-2-carbonyl)-amino]-etliyl}-amide; 2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid {2-[cyciopropyimethyl-(4 nielhyl- biphenyl-2-carbonyl)-amino]-ethyl}-amide; 2,3-Dihydro-benzo[1,4]dioxine-5-carboxylic acid {2-[cyclopropylmethyl-(4'-ftuoro- biphenyl-2-carbonyl)-amino]-ethyl}-amide; 2-Cyclopropyl-5-phenyi-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)- amino]-ethyl}-cyclopropylmethyl-amide; 2-Cyclopropyl-5-/T7-tolyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)- amino]-ethyl}-cyclopropylmethyl-amide; 2-Cyclopropyl-5-(3-methoxy-phenyl)-thiazole-4-carboxy(ic acid {2-[(bertzofuran-4- carbonyl)-amino]-ethyl}-cyclopropylnnethyl-amide 2-Annino-5-m-tolyl-thiazole-4-carboxylic acid {2-[(benzoluiaii 4-carbonyl)-arnino] ethyl}-cyclopropylmetliyl-amide; 2-Amino-5-(3-fluoro-phenyl)-thiazole-4-carboxylic acid {2-[(benzofurarv-i . cu ijonyl)- amino]-ethyl}-cyclopropyimethyi-amide; 2-Amino-5-{3-methoxy-plienyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4- carbonyi)-amino]-etliyl}-cyclopropylmethyl-amide; 2-Amino-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid ■f?-['fbenzofuran-4-carbonyl)- amino]-ethyl}-cyclopropylmethyl-annide; 2-Amino-5-(3-chloro-phenyl)-tliiazole-4-carboxylic auid {2-[(uenzofuiaii-4-carbonyl)- amino]-ethyl}-cyclopropylmethyl-amide; 2-Amino-5-phenyl-thiazole-4-carboxylic acid{2-[(benzofuran-4-carbonyl)-amino]- ethyl}-cyclopropylmetliyl-amide; 2-Bromo-5-(3-methoxy-phenyl)-thiazole-4-carboxylicacia {2-[(benzofuran-4- carbonyl)-amino]-ethyl}-cyclopropylmethyl-amide; 2-Bronno-5-p-tolyl-thiazole-4-carboxylic acid {2-[(benzofuran-4-carbonyl)-amino]- etliyl}-cyclopropylmetlnyl-amide; 5-(2-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid{2-[(benzofuran-4-carbonyl)- amino]-ethyl}-cyclopropyimethyl-amide; 2-Methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid {2-[(benzofuran-4- carbonyl)-amino]-ethyl}-cyclopropylmethyl-amide; 5-(3-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid {2-[(ben/uiuran 4-carboiiyl) amino]-ethyl}~cyclopropylnnethyl-amide; 2-Methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid {2- [(benzofLiran 4- carbonyl)-amino]-ethyl}-cyclopropylmethyl-amide; 5-(4-Chioro-phenyl)-2-methyl-thiazole-4-carboxylic acia {2-[(benzofuraii 4 caiLuiiyl) amino]-ethyl}-cyclopropylmethyl-annide; 5-(3-Methoxy-phenyl)-2-nnethyl-thia2ole-4-carboxylic acid {2-[(ben2ofuran-4- carbonyl)-amino]-ethyl}-cyclopropylmethyl-amide; 5-(3-Cyano-phenyl)-2-methyl-thiazole-4-carboxylic acid {2-[(benz.ofuran-4-carbonyl)- amino]-ethyl}-cyclopropylnnethyl-amide; 5-(3,4-Dimethyl-phenyl)-2-methyl-thiazole-4-carboxylir acid {2-[(benzofuran-4- carbonyl)-amino]-ethyl}-cyclopropyinnethyl-amide; 2-Methyl-5-p-tolyl-thiazole-4-carboxyiic acid {2-[(benzofuran-4-carbonyl)-amino]- ethylj-cyciopropylmethyl-amide; Benzofuran-4-carboxylic acid {2-[cyclopropylmethyl-(3'-melhyi-biphenyI 2 carbonyl)- amino]-ethyl}-amide; Benzofuran-4-carboxylicacid{2-[cyclopropylmethyl-(4'-methyl-biphenyl-2-carbonyl)- amino]-ethyl}-amide; and Benzofuran-4-carboxylicacid{2-[cyclopropylmethyl-(4'-fluoro-biphenyl-2-carbonyl)- amino]-ethyl}-amide; or a salt of such a compound. 10. A pharmaceutical composition containing, as active principle, a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient. 11. A compound of any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for use as medicament. 12. A compound according to any of claims 1 to 9, or a pharmaceutically acceptable salt thereof, for the the prevention or treatment of diseases selected from the group consisting of all types of sleep disorders, of stress-related syndromes, of psychoactive substance use and abuse, of cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders. 13. Use of a compound according to any of claims 1 to 9, or of a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of all types of sleep disorders, of stress-related syndromes, of psychoactive substance use abuse, of cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders.